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Abstract 
Metastatic prostate cancer continues to be a leading cause of cancer-related death in 
men. Increased incidences and mortality have been reported globally, although 
treatment of locally confined prostate cancer has been shown to be successful. 
However, aggressive and incurable castration-resistant prostate cancer (CRPC) is a 
major clinical concern.  
The combination of radiotherapy and androgen deprivation therapy (ADT) is the 
current standard-of-care treatment strategy for prostate cancer (PCa). The androgen-
dependent stage of tumour is successfully managed, until the cancer switches to 
androgen-independence when resistance to treatment severe. The mechanism 
underlying this switch is still not clear and poorly understood. However, the implicated 
survival pathways of PI3K/mTOR, EGFR and AR might help explain remissions of PCa 
after treatment. Thus, the rationale for this study was to target these pathways with 
respective inhibitors, namely, MDV3100 (for AR), AG-1478 (for EGFR), and NVP-
BEZ235 (for PI3K and mTOR).  
The “traditional” prostate cancer cell lines, (DU145 and LNCaP), which are derived 
from metastatic regions, and (1542N and BPH-1) from normal tissue and a primary 
benign tumour, respectively, served as biological models in this research. The 
following were investigated: (1) androgen sensitivity of cell lines, (2) the intrinsic 
cellular radiosensitivity, (3) the cytotoxicity of specific inhibitors of AR, EGFR, PI3K 
and mTOR, (4) interaction of the respective inhibitors, and (5) the radiomodulatory 
effects of inhibitors, either singly or in combination. 
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The “classical” androgen-independent cell lines were found to switch into androgen-
dependence when treated with high concentrations of 5α-DHT.  
 
Very strong synergistic interactions of inhibitors were demonstrated in all cell lines, 
except the LNCaP cell line in which inhibitors were antagonistic. Concomitant use of 
these inhibitors in intrinsically androgen-dependent prostate cancers might not be 
beneficial. The use of inhibitor cocktails with radiation at low doses (2 Gy) is highly 
desirable as the normal cells were protected, especially with the dual inhibitor of 
PI3K/mTOR (NVP-BEZ235). However, at higher doses (6 Gy) the potential benefit is 
great in tumour cell lines, but very limited in the normal cell line. Therefore, at fractional 
doses of relevance to conventional radiotherapy, use of cocktails containing the 
PI3K/mTOR inhibitor as an adjuvant may be beneficial in the management of 
androgen-dependent cancer.  
 
It is concluded that these findings might assist in the design of more effective treatment 
approaches for cancers that typically display resistance to radiotherapy and 
chemotherapy. 
 
  
Stellenbosch University https://scholar.sun.ac.za
v 
Opsomming 
Metastatiese prostaatkanker (PCa) bly steeds een van die leidende oorsake van 
kankerverwante sterfte in mans. 'n Toename in die insidensie en mortaliteit is 
wêreldwyd gerapporteer, alhoewel behandeling van prostaatkanker wat lokaal beperk 
is, bewys is om suksesvol te wees. Daarenteen bly aggressiewe en ongeneeslike 
kastrasieweerstandige prostaatkanker (KWPK) 'n ernstige kliniese probleem.  
Die kombinasie van radioterapie en androgeenontnemingsterapie (AOT) is die huidige 
standaardbehandelingstrategie vir PCa. Die androgeenafhanklike stadium van die 
tumor word suksesvol beheer, totdat die kanker oorgaan na 
androgeenonafhanklikheid, wat ernstige weerstand teen behandeling beteken. Die 
onderliggende meganisme, wat hierdie omskakeling bewerkstellig, is steeds nog 
onduidelik en onverklaarbaar. Die paaie van PI3K/mTOR, EGFR en AR mag van 
waarde wees om remissies van PCa na behandeling te verklaar. Teen hierdie 
agtergrond is die doelwit van hierdie studie om hierdie paaie te teiken met die 
onderskeie inhibitore, naamlik; MDV3100 (vir AR), AG-1478 (vir EGFR) en NVP-
BEZ235 (vir PI3K/mTOR).  
Die tradisionele prostaatkankersellyne (DU145 en LNCaP), verkry vanaf metastatiese 
streke, asook (1542N en BPH-1), verkry vanaf normale weefsels en 'n primêre benigne 
tumor respektiewelik, het gedien as biologiese modelle in hierdie navorsing. Die 
volgende aspekte is ondersoek: (1) Androgeensensitiwiteit van sellyne; (2) Die 
intrinsieke radiosensitiwiteit van die selle; (3) Die sitotoksisiteit van spesifieke 
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inhibitore van AR, EGFR, PI3K en mTOR; (4) Interaksie van die onderskeie inhibitore; 
(5) Die radiomodulerende uitwerking van inhibitore, afsonderlik of gekombineerd.  
 
Dit is gevind dat die “klassieke” androgeen- onafhanklike sellyne omgeskakel het na 
androgeenafhankheid wanneer dit behandel is met hoë konsentrasies van 5α-
dihidrotestosteroon (5α-DHT).  
 
Merkwaardige sinergistiese interaksies tussen inhibitore is gedemonstreer in alle 
sellyne, behalwe die LNCaP–sellyn waar die inhibitore antagonisties was. 
Gekombineende gebruik van hierdie inhibitore in intrinsieke androgeenafhanklike 
prostaatkankers mag nie voordelig wees nie. Die gebruik van inhibitormengsels saam 
met bestraling teen n lae dosis (2Gy) is hoogs wenslik, omdat die normale selle 
beskerm is, veral met die dubbele inhibitor van PI3K/mTOR (NVP-BEZ235). 
Daarenteen is die potensiël voordeel van n hoë dosis (6Gy) groot in tumorsellyne, 
maar baie beperk teen die normale sellyne. Gevolglik, teen fraksionele dosisse van 
betekenis by konvensionele radioterapie, mag die aanwending van 'n kombinasie van 
die PI3K/mTOR – inhibitor as adjuvant voordelig wees by die behandeling van 
androgeenafhanklike kanker. 
 
Die gevogtrekking word gemaak dat hierdie bevindinge kan bydra tot die ontwerp van 
meer doeltreffende behandelingstrategieë teen kankers wat tipies weerstandig is teen 
radioterapie en chemoterapie. 
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1.1. Introduction 
 
Prostate cancer (PCa) remains one of the commonly diagnosed cancers, especially 
in men over the age of 40 years, with an increasing incidence and mortality globally 
(Taitt, 2018; Bray et al., 2018). Several treatment options are available for localised 
and early stage PCa, however, ongoing research is needed to improve the clinical 
outcome of metastasised and resistant PCa (Heidenreich et al., 2011; Gómez-Millán 
et al., 2015; Litwin and Tan, 2017). Understanding the biology, genetic basis, and 
risk stratification of the prostate, holistically, before treatment, is very advantageous 
in the management of PCa. 
 
Radical prostatectomy, external-beam radiation therapy (EBRT) and brachytherapy 
are the gold standards in the treatment of localised PCa and have proven to be 
beneficial for post-operative local control. However, radioresistance remains the 
main clinical challenge, which finally leads to tumour recurrences (An et al., 2007; 
Heidenreich et al., 2011; Heidenreich et al., 2014; Chang et al., 2015; Ost et al., 
2016). As the disease progresses and the genotype changes, treatment strategies 
need to be altered to address the problem. Chemotherapeutics, such as 
enzalutamide, abiraterone and prednisone have yielded positive outcomes but for 
the toxicity to normal tissue (An et al., 2007; Kuban et al., 2008; Wei et al., 2017; 
Taneja, 2018). However, normal tissue can be spared while therapy is administrated 
by dose alterations, and by employing radiation and chemotherapy combination 
strategies (Blagosklonny et al., 2002; Maleka et al., 2015). This has shown great 
results in addressing the side effects of high doses and toxicity of chemotherapy to 
the patients ( Akudugu et al., 2008; Hamunyela et al., 2017; Wei et al., 2017). 
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Maleka and colleagues demonstrated that NVP-BEZ235 results in better cancer 
control than traditional radiotherapy (Maleka et al., 2019). Advanced research has 
resulted in a wealth of knowledge to address the limitations of conventional 
treatment, and said limitations can be addressed with non-conventional therapy, 
such as immunotherapy and targeted therapy. 
  
Once the biology of PCa is appreciated and fully understood, treatment can be 
planned with the goal being (1) to protect normal tissue and organs surrounding the 
prostate, such as bladder, rectum, testicles, and (2) destroying the cancerous cells 
within the prostate gland, in the case of localised disease. Knowledge of the 
mechanics of disease targeted-therapy can be combined with conventional treatment 
to achieve long term patient survival.  
 
Targeted therapy looks at the critical pathways involved in the initiation and 
progression of PCa (LoPiccolo et al., 2008; Hurvitz et al., 2013; Kratochwil et al., 
2016). The androgen receptor (AR), at the epicentre of PCa research, paradoxically 
remains neglected and is involved in crosstalk between pathways (Sadar, 1999; 
Migliaccio et al., 2006). Since the disease is driven by hormones, it should be 
controlled by hormones, for example, androgen deprivation therapy (ADT), but 
resistance limits therapeutic advantage (Lai et al., 2013; Caffo et al., 2015). 
Capitalising on the crosstalk between pathways by targeting the PI3K/mTOR/EGFR 
pathway might assist in solving the problem of PCa resistance to hormonal therapy 
(Di Lorenzo et al., 2003; Wang et al., 2008; Carracedo and Pandolfi, 2008; 
Carracedo et al., 2008; Hurvitz et al., 2013). The dual inhibitor of PI3K and mTOR, 
NVP-BEZ235, has been studied in breast, head and neck, and colon cancers 
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(Brachmann et al., 2009; Fokas et al., 2012; Chen et al., 2018). Our previous 
investigations have shown that effects of NVP-BEZ235 may be novel in prostate 
tumours (Maleka et al., 2015). 
 
Cellular exposure to ionising radiation has been proven to activate the epidermal 
growth factor receptor, EGFR, and induce phosphoinositide 3-kinase (PI3K), serine-
threonine protein kinase (Akt) and mammalian target of rapamycin (mTOR) activity 
downstream of the EGFR signalling pathway (Li et al., 2005; Valerie et al., 2007; Lee 
et al., 2008; Sarker et al., 2009; Palacios et al., 2013). Cell survival is promoted by 
this pathway which can also lead to treatment resistance.    
 
In designing novel therapeutic interventions for the treatment or management of 
PCa, molecular mechanisms that are responsible for the development and 
progression of the disease need to be understood. Specifically, the transition of 
prostate tumour cells from androgen-dependent to androgen-independent is crucial 
in developing new treatment approaches (Shen and Abate-Shen, 2010). 
 
The problems that are faced due to acquired resistance to therapy and tumour 
recurrences thus warrant a continuous search for better and alternative treatment 
options for PCa. 
 
1.2. Rationale and Problem Statement 
 
PCa management is faced with numerous clinical challenges though conventional 
therapy has proved to be successful in the management of localised and early 
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diagnostic cases. Clinicians are still battling to address the cellular resistance with 
late diagnostic cases that have metastasised. Resistance can be attributed to 
mutations, over-treatment, and mistreatment, resulting in tumour recurrences 
(LoPiccolo et al., 2008; Eichhorn et al., 2008). Resistance of PCa cells to 
radiotherapy and ADT limits treatment response (Shen and Abate-Shen, 2010; 
Palacios et al., 2013). Cells survive through activation of molecular signalling routes 
such as the EGFR and PI3K/Akt/mTOR pathways (Lee, et al., 2004; Skvortsova et 
al., 2008; Farooqi and Sarkar, 2015). Crosstalk between signalling pathways has 
also been cited as the main reason for resistances and recurrences (Bektas et al., 
2005; Migliaccio et al., 2006; Courtney et al., 2010; Bitting and Armstrong, 2013). 
Furthermore, inhibition of the androgen receptor signalling pathway in ADT initially 
reduces androgen-dependent prostate tumour growth (Pienta and Bradley, 2006; 
Ryan and Tindall, 2011; Carrión-Salip et al., 2012). This is often followed by a 
relapse with the disease presenting as androgen-independent. Development of 
androgen-independence may be due to an EGFR-mediated activation of the 
PI3K/Akt/mTOR pathway, leading to enhanced tumour cell survival (Traish and 
Morgentaler, 2009; Bitting and Armstrong, 2013; Taneja, 2018; Tomasello et al., 
2018). Development of new treatment strategies are needed to address these 
therapeutic dilemmas.  
 
1.3. Hypothesis 
 
It is hypothesised that targeting the EGFR family proteins, PI3K and mTOR, and the 
androgen receptor pathway, with specific inhibitors, singly or in combination, can 
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significantly sensitise androgen dependent and androgen independent prostate 
cancer cells to low therapeutic doses of ionising radiation. 
 
1.4. Aims and Objectives 
 
In search of alternative treatment approaches this current study aims to understand 
the molecular mechanisms involved in the evolution of prostate cancer, specifically 
the cross-talk that takes place during survival pathway inhibition and cells surviving 
ionising radiation treatment, by identifying and validating the expression of potential 
therapeutic targets responsible for the survival pathways: the PI3K/Akt/mTOR, 
EGFR and AR signalling pathways. The idea is to sensitise prostate cancer cells to 
radiation therapy. It is hoped that an improved outcome to radiotherapy will be 
achieved by concomitant treatment of prostate cells with low doses of ionising 
radiation and NVP-BEZ235 (dual inhibitor of PI3K and mTOR), Tyrphostin AG-1478 
(inhibitor of EGFR) and MDV3100 (inhibitor of AR), either singly or as a cocktail.  
 
These novel therapies will improve the outcome of radiotherapy by targeting the 
molecular elements that drive the radiation resistance. It is expected that this 
approach will make a significant contribution towards the formulation of patient-
specific therapeutic cocktails that will revolutionise the treatment of prostate cancer.  
 
The overarching aim of the study was to sensitise androgen dependent and 
independent prostate cancer cells by inhibiting potential therapeutic targets with their 
respective inhibitors. For this, the following objectives were pursued:  
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 Determine the intrinsic radiosensitivity of a panel of benign and 
malignant prostate cancer cell lines following exposure to X-rays. 
 Determine the androgen sensitivity of each cell line.  
 Determine the cytotoxicity of specific inhibitors of AR, EGFR, PI3K and 
mTOR in each cell line. 
 Evaluate the roles of AR, EGFR, PI3K and mTOR in androgen 
dependent and independent cell lines with respect to radiosensitivity.  
 Determine the radiomodulatory effects of the abovementioned 
inhibitors, singly or in combination, in each cell line. 
 
1.5. Significance of the Study 
 
This research work demonstrates the following: 
 High concentration of 5-dihydrotestosterone (5-DHT) switches 
androgen independent cells to androgen dependent. 
 NVP–BEZ235 has the ability to protect normal cells, at the same time 
giving a therapeutic benefit to cancer cells. 
 NVP–BEZ235 has a therapeutic advantage at EC50 over X-rays at D50. 
 A very strong synergism was demonstrated between NVP–BEZ235 
and MVD3100.  
 Pre-treatment of apparently normal and malignant human prostate cells 
with specific inhibitors of EGFR, PI3K, mTOR and AR, singly or in 
combination, sensitises PCa cells to low and high doses of ionising 
radiation. 
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1.6. Delineations 
 
This study used inhibitors of AR, EGFR, PI3K and mTOR to sensitise four prostate 
cell lines (1542N, BPH-1, DU145 and LNCaP). These cell lines express the 
abovementioned targets, but the expression levels of said targets, reported in 
several studies, were not determined prior to inhibition. 
 
The research variables determined in this study are (1) the intrinsic cellular 
radiosensitivity of the cell lines, (2) the cytotoxicity of specific inhibitors of AR, EGFR, 
PI3K and mTOR, (3) the radiomodulatory effects of inhibitors, either singly or in 
combination. 
 
Clonogenic cell survival following ionising radiation was determined to compare the 
intrinsic cellular radiosensitivity of four cell lines. Cytotoxicity was determined, using 
the colony forming assay, by extracting the equivalent concentration for 50% cell kill 
(EC50) for each cell line. Combination indices were determined from the cytotoxicity 
data in order to decide on the best inhibitor combination to be used in a cocktail, in 
which radiation modifying factors were derived to determine their impact on cellular 
radiosensitivity. 
 
These research variables were deemed sufficient to prove the research hypothesis. 
Some of the data presented here have been published (Maleka et al., 2019; 
Appendix A) and presented at Conferences. 
 
  
Stellenbosch University https://scholar.sun.ac.za
9 
 
1.7. Background Literature 
 
1.7.1. The Prostate Gland 
 
The male reproduction system consists of the penis, testicles and the prostate, a 
walnut-shaped organ. The main and important function of the prostate is the 
production of the fluid that transports the sperm through the urethra. It is surrounded 
by the bladder and the rectum. 
  
1.7.2. Incidences 
 
Prostate cancer is a significant human health concern because it is the most 
diagnosed form of cancer in men (Rebbeck et al., 2013; Ferlay et al., 2019). 
Globally, and second to lung cancer, PCa remains one of the leading causes of 
cancer deaths amongst men. In developing countries in sub-Saharan Africa, 
including South Africa, the incidence of this disease is increasing rapidly (Rebbeck et 
al., 2013; Taitt, 2018) due to medical technology advancement, increased screening 
and awareness, a high quality of living, and an ageing population (Traish and 
Morgentaler, 2009; Rebbeck et al., 2013). Increasing mortality rates remain 
problematic because of the lack of curative treatment, especially in patients with 
androgen resistant metastatic disease (Scher et al., 2010; de Bono et al., 2010; 
Litwin and Tan, 2017). 
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1.7.3. Hallmarks of Cancer 
 
Different mechanisms in the human body, such as apoptosis, necrosis and 
autophagy, regulate the growth of normal cells. When normal cells are not controlled 
due to a failure of these mechanisms, these cells evade the immune system and 
divide uncontrollably, resulting in a growth known as cancer. These abnormal cells 
become resistant and continue to spread, acquiring characteristics that aid their 
replication.  
 
Figure 1.1: The Hallmarks of cancer as proposed by Hanahan and Weinberg (Hanahan and 
Weinberg, 2000). 
 
Briefly, the six hallmarks depictured in Figure 1.1 include: (1) sustaining proliferative 
signalling for survival, (2) evading growth suppressors, (3) activating invasion and 
metastasis, (4) enabling replicative immortality, (5) inducing angiogenesis, which is 
the generation of blood vessels for tumour survival and growth, and (6) resisting cell 
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death by apoptosis, a mechanism that signals damaged cells to die (Hanahan and 
Weinberg, 2000; Pavlova  and Thompson, 2016; Flavahan et al., 2017). 
 
1.7.4. Management of PCa 
 
The management and treatment planning of PCa has always been aligned with 
patient safety and survival (Heidenreich et al., 2011; Hannan et al., 2016; Wei et al., 
2017). The goal of an effective treatment regimen (curative or palliative), ideally, 
must result in less morbidity, decreased recurrence of tumours, and be specific for 
destroying cancer cells without damaging normal cells (Potiron et al., 2013). Lastly, 
decisions are usually made as to the patient’s preference (Heidenreich et al., 2014; 
Lowrance et al., 2018). 
 
Through research and development, effective therapies have been developed to 
address the heterogeneity of PCa, but no curative therapeutic strategies exist 
(Sanchez et al., 2011). Most patients with organ-confined disease undergo radical 
prostatectomy, radiotherapy, or androgen deprivation therapy (Madsen et al., 2007; 
Rusthoven et al., 2016). Complications after treatment for prostate cancer are well 
documented (An et al., 2007; LoPiccolo et al., 2008; Hurvitz et al., 2013; Wei et al., 
2017). 
 
1.7.5. Conventional Therapies for PCa 
 
In clinical settings, over 60% of solid tumours are treated with radiation, or a 
combination of radiation and other modalities. The primary treatment for localised 
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prostate cancer is ionising radiation, or complete removal of the prostate (radical 
prostatectomy). Due to resistance to therapy many patients relapse, resulting in re-
growth of the cancer. The next step to follow is androgen deprivation therapy, 
because cancer cells die due to androgen blockade. Most tumours develop 
resistance, eventually growing in the absence of testosterone (Lai et al., 2013). This 
is known as hormone relapse, and patients in this stage are defined as hormone-
refractory, also known as castration-resistant prostate cancer (CRPCa) (Guérin et 
al., 2010; Jain et al, 2012; Berkovic et al., 2013; Antonarakis et al., 2015).  
 
After hormone relapse, therapeutic options are limited. Chemotherapy is also utilised 
in the clinical setting but has been found to be ineffective in prostate cancer. It leads 
to toxicity with severe side effects to patients (de Bono et al., 2010; Bitting and 
Armstrong, 2013). Prostate cancer is managed according to the stage of the cancer. 
In Stage I, the cancer is small and confined within the prostate and grows slowly; in 
Stage II, the cancer is confined within the prostate, but the likelihood of spread is 
greater than in Stage I; in Stage III, the cancer has spread beyond the prostate but 
not to the lymph nodes or other organs; and in Stage IV, the cancer has spread 
systematically beyond the prostate to the lymph nodes and other organs (Schlomm 
et al., 2007; Heidenreich et al., 2011). 
 
Localised disease, i.e. Stages I and II, have various alternatives for clinical 
management, the first being surveillance (or watchful waiting), followed by traditional 
radiation therapy, and, depending on age, surgery will be employed (Heidenreich et 
al., 2011; Heidenreich et al., 2014; Litwin and Tan, 2017). Once the disease has 
spread beyond the confines of the organ i.e. Stages III and IV, the disease has 
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metastasised (Heidenreich et al., 2014). The approach to managing the disease 
must now change. Systematic clinical management with chemotherapy is then 
employed. There are numerous drugs, for example, enzalutamide, abiraterone and 
prednisone that have been used successfully in chemotherapy, improving the 
survival of patients, but the challenge is treatment induced resistance (de Bono et 
al., 2010; Bitting and Armstrong, 2013; Ryan et al., 2015; Wei et al., 2017).   
 
Advanced prostate cancers are responsive to ADT at the beginning of treatment, but 
tend to become hormone refractory and resistant to therapy at a later stage (Shen 
and Abate-Shen, 2010; Carrión-Salip et al., 2012; Gómez-Millán et al., 2015). In 
addition, ADT does not entirely eliminate androgen independent cancer cells in 
advanced prostate cancer. Although chemotherapy with enzalutamide, abiraterone 
and prednisone appears to be effective for castration-resistant prostate cancers 
which do not respond to ADT, the median survival period is only about 4 months 
(Azad et al., 2015; Ryan et al., 2015; Antonarakis et al., 2015). 
 
Below is a list of conventional therapies and their limitations:  
 Radiotherapy: the problem is toxicity and the lack of specificity to the site of 
the tumour. Normal cells are also killed during treatment. 
 Surgery is invasive and can only be performed on localised prostate cancer. 
In addition to complications, such as incisional hernia and rectal injury, 
surgery has a high morbidity rate. 
 Long-term hormonal therapy, also known as ADT, reduces the quality of life of 
an individual resulting in a loss of stamina, atrophy, premature osteoporosis 
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and increased fatigue (Spitzweg et al., 2000). Most prostate cancers develop 
resistance to ADT (Taitt, 2018). 
 Chemotherapy involves very toxic drugs that kill fast growing cells, as well as, 
normal cells. For example, blood cells are destroyed during chemotherapy, 
and immunological function is suppressed and compromised. This results in 
infections and poor immune response.  
 
1.7.6. Targeted Therapy 
 
Targeted therapy/personalised medicine has been studied in depth, especially in 
patients with breast and head-and-neck cancers, in addressing the challenges faced 
with conventional treatment (Small, 2004; Bitting and Armstrong, 2013; Hurvitz et al., 
2013; Kratochwil et al., 2016). Recently, Maleka and colleagues looked at targeted 
therapy as an alternative to traditional radiotherapy (Maleka et al., 2015; 2019). 
Studies on signalling pathways, such as those involving EGFR, PI3K, Akt, and 
mTOR (LoPiccolo et al., 2008; Courtney et al., 2010; Choi et al., 2010; Li et al., 
2012; Bitting and Armstrong, 2013), might lead to the identification of potentially 
effective therapeutic interventions for prostate cancer.  
 
1.7.7. The PI3K/Akt/mTOR Signalling Pathway  
 
The PI3K pathway is a non-linear pathway which transmits signals through protein-
protein or lipid-protein interaction, playing a very critical regulatory function in cellular 
processes such as cell survival, protein synthesis, proliferation and glucose 
metabolism (Courtney et al., 2010; Mayer and Arteaga, 2015). 
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These are the most studied and researched pathways in cancer therapy. 
PI3K/Akt/mTOR leads to cell survival, and mitogen-activated protein kinase (MAPK) 
leads to cell proliferation. Both pathways are implicated in carcinogenesis thus 
making them very interesting signalling pathways in targeted therapy (Sarker et al., 
2009). Prostate cancer cells utilise multiple molecular pathways to proliferate, 
survive and invade tissue during the course of tumour progression (Shukla et al., 
2007; Sarker et al., 2009). Among several prostate signalling pathways, upregulation 
of PI3K/Akt/mTOR signalling through mutations in the PTEN gene and activation of 
growth factor receptors are important for the identification of therapeutic targets 
(Carracedo et al., 2008; Sarker et al., 2009; Shen and Abate-Shen, 2010). 
 
The PI3K/Akt/mTOR pathway is fundamental to the metastatic potential of PCa and 
provides a strong rationale for targeting this pathway in prostate disease. 
 
1.7.8. Inhibition of the PI3K/ Akt /mTOR Signalling Pathway  
 
Breast and head-and-neck cancer treatments have been very successful, targeting 
the PI3K/Akt/mTOR pathway, given its importance in cell survival signalling 
(Sanchez et al., 2011; Hurvitz et al., 2013). Since it is indicated that PCa has a high 
prevalence of activation of this pathway, its inhibition has great potential for improved 
clinical outcome in men with advanced prostate cancer. 
 
The catalytic domain of the p110 subunits and mTOR belong to the 
phosphatidylinositol kinase-related family of kinases, and are, therefore, structurally 
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similar. Targeting more than one target protein in the survival pathway is the 
direction in which targeted therapy research is headed, and recent clinical studies 
have shown the benefit of switching off more than a single target protein (LoPiccolo 
et al., 2008; Li et al., 2012). The inhibition of the PI3K/Akt/mTOR pathway, termed 
dual-inhibition, means that two sites in the PI3K/Akt/mTOR pathway are targeted, 
resulting in optimum blockage of the pathway (Serra et al., 2008; Chen et al., 2018). 
Compared to single targeting of specific components of the pathway, a dual inhibitor 
has the potential of inhibiting all the PI3K catalytic isoforms, thus effectively switching 
off the pathway completely and overcoming feedback inhibition, normally observed 
with mTORC1  inhibitors (Carracedo and Pandolfi, 2008; Carracedo et al., 2008). 
 
LY294002, a dual PI3K-mTOR inhibitor, has been used in preclinical studies, but the 
disadvantage of this agent is that it is too toxic for clinical settings (Toulany et al., 
2006; Shukla et al., 2007). Other dual inhibitors, such as the NVP-BEZ235 and NVP-
BGT226 have entered phase 1 clinical trials. NVP-BEZ235 has been extensively 
evaluated clinically, with positive results. It has been shown to be well-tolerated, with 
no significant changes in the body weight of mice, and slowed the growth of PTEN-
deficient human cancer cells (Serra et al., 2008; Fokas et al., 2012; Potiron et al., 
2013). In the clinic, NVP-BEZ235 has been well-tolerated in patients with solid 
tumours (Choi et al., 2010). 
  
1.7.9. Epidermal Growth Factor Receptor (EGFR) 
 
The epidermal growth factor receptor (EGFR) family, consists of four members, 
namely; ErbB1 (EGFR), ErbB2, ErbB3 and ErbB4 (Barton et al., 2001). They are 
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composed of 3 functional domains, namely, an extracellular ligand binding domain, a 
hydrophobic trans-membrane, and an intracellular domain that has catalytic tyrosine 
kinase activity. 
 
Activation of the EGFR signalling pathway takes place when the EGFR family of 
peptides binds to their receptive extracellular domains (Traish and Morgentaler, 
2009). Dimerisation of the receptor takes place with another member of the ErbB 
family or an EGFR monomer. This is followed by the induction of intrinsic protein 
tyrosine kinase activity, and tyrosine autophosphorylation, leading to the recruitment 
of several intracellular substrates, resulting in mutagenic signalling and other cellular 
activities. The most important and well-studied signalling route of the EGFR is the 
Ras-Raf-mitogen-activated protein kinase (MAPK) pathway and (PI3K) (Sarker et al., 
2009; Shen and Abate-Shen, 2010). 
 
The ErbB receptors are expressed in a variety of epithelial tissues where they play 
an important role in development, proliferation and differentiation (Guérin et al., 
2010). High levels of EGFR have been observed in a variety of tumours, including 
prostate, breast, colorectal and ovarian. Bladder cancer and renal cell cancer, too, 
are reported to express EGFR. ErbB2 and EGFR have been implicated in the 
development of numerous cancers, including PCa. Genetic changes detected in the 
cancers lead to the deregulation of receptors, resulting in the overexpression of 
EGFR proteins. Activation of EGFR has been shown to enhance tumour growth and 
tumour progression (Guérin et al., 2010; Ghosh et al., 2005; Carrión-Salip et al., 
2012). 
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1.7.10. Inhibition of the EGFR 
 
Currently, targeted therapies in oncology include the two major categories of 
molecules: monoclonal antibodies and tyrosine kinase inhibitors (TKI). These are 
new therapeutic approaches for PCa currently in the clinic. They are directed against 
the growth factor signalling pathway involving the EGFR family of receptors and the 
downstream components that transduce signals to the cell nucleus. Preclinical 
studies have demonstrated that EGFR-targeting agents have the potential to be 
used in combination with cytotoxic chemotherapy and radiotherapy (Li et al., 2012). 
IMC-C225 (cetuximab) has been shown to enhance the effects of cytotoxic agents 
and radiotherapy (Liang et al., 2003; Small, 2004; Harris, 2004; Dhupkar et al., 2010; 
Liu et al., 2010). 
  
1.7.11. The Role of Androgen in Prostate Cancer 
 
The function of the prostate is initially controlled by androgens which are important in 
maintaining and regulating the expression of specific genes (Traish and Morgentaler, 
2009; Ryan and Tindall, 2011). EGFR and their respective receptors mediate 
proliferation of the androgen-independent PCa and may interact with androgen 
receptors in the absence of androgen ligand binding, constituting an essential 
signalling pathway for tumour growth, invasiveness and metastasis (Ghosh et al., 
2005; Carrión-Salip et al., 2012).  
   
The majority of prostate tumours are dependent on androgens for growth and 
advanced prostate cancers are generally treated with ADT (Sadar, 1999; Jain et al., 
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2012). However, the majority of prostate cancers have been known to develop 
resistance against ADT (Pienta and Bradley, 2006; Jain et al., 2012). Another factor 
known to increase tumour cell resistance to treatment is the presence of 
overexpressed or activated oncogenes, or the loss of function in tumour suppressor 
proteins (Cully et al., 2006).  
 
Prostate cancer is a disease of androgens. Androgens control the growth and 
function of the prostate through a series of events involving the metabolism of 
testosterone into 5α-dihydrotestosterone (5α-DHT) by the enzyme 5α-reductase 
(Chen et al., 2008). This makes androgens crucial in the maintenance of prostate 
homeostasis, and in the regulation of proteins like EGFR, PI3K, Akt, and mTOR, 
which are involved in cellular proliferation and survival (Ghosh et al., 2005; Carrión-
Salip et al., 2012). 
 
In androgen-dependent PCa, cell proliferation and survival are mainly controlled by 
androgens through androgen receptors  (Chen et al., 2008). The AR pathway can be 
effectively regulated because the cells depend on androgens for survival, and are 
responsive to ADT. However, in androgen-independent PCa, cell proliferation and 
survival are facilitated by alternative pathways, such as EGFR and PI3K (Ghosh et 
al., 2005; Carrión-Salip et al., 2012). Interestingly, EGFR may be activated through 
the signalling of PI3K/Akt/mTOR, an alternative means of survival for androgen-
independent cells in the absence of androgens. This consequently leads to tumour 
growth and invasion, and ultimately metastasis, making available treatment options 
ineffective. 
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The AR and EGFR are related to each other because of the regulatory mechanisms 
observed between the respective pathways (Knudsen and Penning, 2010). The 
EGFR, through PI3K/Akt/mTOR, is the driving force of androgen-independent PCa 
cell survival (Carrión-Salip et al., 2012). The PI3K/Akt/mTOR pathway also plays a 
central role in the development and progression of cancer by regulating cell 
differentiation, growth, metabolism, migration and survival. 
 
1.7.12. Regulation of EGFR and PI3K Pathways by Androgen  
 
The development of prostate cancer involves a series of events, including changes 
in the function of numerous growth regulatory signalling components such as AR, 
EGFR and PI3K/Akt/mTOR. Expression of EGFR in normal prostate tissue is 
suppressed by androgen, while in PCa it is upregulated by androgens (Traish and 
Morgentaler, 2009; Knudsen and Penning, 2010). This suggests that in advanced 
PCa, EGFR is highly expressed due to the upregulation of androgens. Increased 
EGFR in prostate cancer is correlated with a high Gleason score and disease 
progression from androgen-dependent to androgen-independent. EGFR is a 
transmembrane receptor and its expression varies significantly in relation to 
androgen dependence. Activity of EGFR predominantly phosphorylates specific 
tyrosine residues activating several signalling cascades, including the PI3K pathway 
which controls multiple biological processes of cancer.  
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1.7.13. Cross-Talk between AR, EGFR and PI3K Signalling Pathways in 
Prostate Cancer 
 
EGFR and PI3K are positively correlated with androgen-independence (Sadar, 1999; 
Carrión-Salip et al., 2012). The expression of EGFR and PI3K pathway proteins 
increases as the PCa progresses from androgen-dependent to androgen-
independent. Disease relapse and progression from androgen-dependent to 
independent are correlated with the expression of EGFR, a phenomenon that could 
be important in cellular response to therapeutic agents (Traish and Morgentaler, 
2009). The increase in expression of pathway components may offer options for 
more effective targeted therapies in androgen-independent prostate cancer.  
 
The AR is highly expressed in the majority of androgen-independent prostate 
cancers, suggesting that the AR signalling pathway is activated in the absence of 
androgens (Lonergan and Tindall, 2011). Cross-talk between AR and EGFR, through 
the PI3K pathway, has been demonstrated and supported by preclinical models 
(Sadar, 1999; Carracedo et al., 2008; Joshi et al., 2015). This cross-talk may present 
itself as an important pathway during PCa progression, giving cells a survival 
advantage, and might serve as a potential target for therapy. The cross-talk further 
emphasises the importance of combination therapy for optimum tumour control. 
 
Androgen deprivation therapy is currently used for patients with metastatic PCa, in 
conjunction with regimens involving the blocking of androgen synthesis by 
ketoconazole and Abirateratone, lowering of AR protein levels through heat shock 
protein 90 (Hsp90) chaperone inhibitors, and degrading of protein with ansamycin 
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antibodies (Li et al., 2010; Carver et al., 2011; Schweizer et al., 2012). This 
combined approach has become necessary due to the inability of the ADT to 
completely block the survival pathway of androgen-independent tumour cells 
(Thamilselvan et al., 2017; Scott, 2017). Activation of the PI3K pathway is associated 
with androgen signalling and may, in part, be responsible for the castration-resistant 
phenotype observed in metastatic PCa (Bitting and Armstrong, 2013). It has been 
suggested that this resistance could be reversed by inhibiting the PI3K and EGFR 
pathways to restore the AR signalling pathway (Carver et al., 2011). This would 
imply the reversal of androgen-independence to androgen-dependence and should, 
therefore, sensitise cells to ADT. Also, inhibition of AR can activate the PI3K 
pathway and give rise to a survival advantage (Carver et al., 2011; Thamilselvan et 
al., 2017; Scott, 2017). These findings would suggest that targeting EGFR, AR, PI3K 
and mTOR might potentially be a useful therapeutic strategy. 
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CHAPTER 2: MATERIALS AND 
METHODS 
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2.1. Study Location and Ethical Consideration 
 
All experiments were performed in the Division of Radiobiology, Faculty of Medicine 
and Health Sciences, Stellenbosch University, Tygerberg. The study was approved 
by the Health Research Ethics Committee (HREC) of the Faculty of Medicine and 
Health Sciences, Stellenbosch University, South Africa (HREC Reference #: 
X19/02/004; Appendix B). 
 
2.2. Reagents for Colony Forming Assay 
 
Fixative 
The fixative for clonogenic cell assays consisted of a mixture of glacial acetic acid, 
methanol and deionised water, in the ratio of 1:1:8 (v/v/v), respectively. 
 
Staining Solution 
Colonies were stained with 0.01% Amido black (Naphthol Blue Black) in fixative. 
 
2.3. Specific Inhibitors 
 
NVP-BEZ235 
NVP-BEZ235 (Santa Cruz Biotechnology, Texas, USA, cat # 364429) is a dual 
inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin 
(mTOR), with an inhibitory concentration at 50% (IC50) of 7.5 nM for PI3K and 5 nM 
for mTOR in highly metastatic human prostate tumour cells (Maira et al., 2008; 
Potiron et al., 2013). NVP-BEZ235 has a molecular weight of 469.55 and is soluble 
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in dimethyl sulfoxide (DMSO). It has a chemical formula of C30H23N5O and Figure 2.1 
shows its chemical structure. NVP-BEZ235 was reconstituted as a stock solution of 
106 mM in dimethyl sulfoxide (DMSO) and stored at -20°C until used.  
 
 
Figure 2.1: Chemical structure of NVP-BEZ235. 
 
 
AG-1478 
AG-1478 (Tocris Bioscience, UK, cat # 1276) is an epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor with an IC50 of 3 nM in non-small cell lung cancer 
(Levitzki and Gazit, 1995; Puri and Salgia, 2008). AG-1478 has a molecular weight 
of 315.8 and is soluble in dimethyl sulfoxide (DMSO). It has a chemical formula of 
C16H14CIN3O2 and Figure 2.2 shows its chemical structure. AG-1478 was 
reconstituted as a stock solution of 10 mM in DMSO and stored at -20°C until used.  
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Figure 2.2: Chemical structure of AG-1478. 
 
 
 
MDV3100 
MDV3100 (KareBay Biochem, USA; cat # S1250) is an androgen receptor (AR) 
inhibitor with an IC50 ranging from 4-21 nM. It is a potent oral antagonist to the AR 
that lacks any agonist activity, and prevents nuclear translocation of AR and its 
binding to DNA (Shen and Abate-Shen, 2010). MDV3100 has a molecular weight of 
464.44 and is soluble in dimethyl sulfoxide (DMSO). It has a chemical formula of 
C21H16F4N4O2S and Figure 2.3 shows its chemical structure. For this study, 5 mg 
stock of MDV3100 was reconstituted with 1.076 ml of DMSO, giving a concentration 
of 10 mM, and stored at -20°C until used. 
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  Figure 2.3: Chemical structure of MDV3100 
 
 
 
2.4. Cell Culture Media 
 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, Germany; cat # 4655) 
was supplemented with 10% heat-inactivated FBS (HyClone, UK, cat # 
SV30160.30IH), and penicillin (100 U/ml) / streptomycin (100 µg/ml) solution (Lonza, 
Belgium, cat # DE17-602E). 
 
Roswell Park Memorial Institute medium (RPMI-1640) 
The Roswell Park Memorial Institute medium, RPMI–1640 (Sigma-Aldrich, USA; cat 
# R8758), was supplemented with 0.3 mg/L L-glutamine, 2.0 mg/L sodium 
bicarbonate, 10% heat-inactivated FBS, and penicillin (100 U/ml) / streptomycin (100 
µg/ml). 
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2.5. Cell lines 
 
1542-NPTX (passage 18-31) 
The benign 1542-NPTX (1542N) human prostate epithelial cell line was derived from 
a primary adenocarcinoma of the prostate, and immortalised with E6 and E7 genes 
of the human papilloma virus 16 (Bright et al., 1997), and was used to represent 
normal prostate tissue. The cells were grown in RPMI-1640, supplemented with 10% 
heat-inactivated FBS, and penicillin (100 U/ml) / streptomycin (100 µg/ml). The cell 
line was provided by Professor JRW Masters (Prostate Cancer Research Centre, 
University College London, UK).  
 
DU145 (passage 7-22) 
DU145 is a human prostate cell line which is derived from a metastatic lesion of the 
central nervous system (Stone et al., 1978). DU145 cells have an epithelial-like 
morphology, were grown in Minimum Essential Medium (MEM) (Sigma-Aldrich, 
Germany) supplemented with 10% heat-inactivated FBS, and penicillin (100 U/ml) / 
streptomycin (100 µg/ml). The cell line was obtained from Professor P Bouic (Synexa 
Life Sciences, Montague Gardens, South Africa). 
 
BPH–1 (passage 2-11) 
The benign prostatic hyperplasia-1 (BPH-1) cell line was established from human 
prostate tissue obtained by transurethral resection. Primary cell cultures were 
immortalised with simian virus 40 (SV40) large T-antigen (Hayward et al., 1995).   
For this study, even though BPH-1 cell line is not defined as a cancer, it was 
assumed to be of tumour-derived as it has been suggested that it may be a 
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precursor to PCa (Hayward et al., 1995). The BPH-1 cells have a cobblestone 
appearance in monolayer culture and grows in RPMI-1640 medium supplemented 
with 10% heat-inactivated FBS, and penicillin (100 U/ml) / streptomycin (100 g/ml). 
The cells were obtained from Professor SW Hayward (Department of Urology, 
University of California, USA).  
 
LNCaP (passage 4-13) 
The LNCaP cell line was established from a supraclavicular lymph node metastasis 
of human prostatic adenocarcinoma (Horoszewicz et al., 1983). LNCaP has a 
fibroblastoid morphology, low anchorage potential, is adherent, but grows in 
aggregates and as single cells in RPMI-1640 medium supplemented with 5% heat-
inactivated FBS, and penicillin (100 U/ml) / streptomycin (100 g/ml). The cultures 
require gentle handling at all times because the cells are easily dislodged by tapping, 
shaking or pipetting.  The low anchorage potential is also responsible for the 10-20% 
cell loss during media changes in long-term experiments (Horoszewicz et al., 1983).  
To address this problem, flasks were coated with fibronectin (100 µl of fibronectin in 
15 ml of sterile PBS) and incubated overnight, before use. The cells were obtained 
from Professor Helmut Klocker (Department of Urology, University of Innsbruck, 
Austria). 
 
2.6. Routine Cell Culture, Cryopreservation and Maintenance  
 
The cells were routinely maintained at 37ºC in a humidified atmosphere (95% air and 
5% CO2) in SHEL LAB incubators (Sheldon Manufacturing Inc, USA). Aseptic 
techniques were used and all cell culture procedures were carried out in vertical laminar 
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flow cabinets. Cells were routinely grown in 75 cm2 flasks, and passaged when culture 
confluency was at 80-90%. 
  
For cryopreservation, cells were trypsinised, pelleted by centrifugation (4000 RPM for 5 
minutes), resuspended in a mixture of 0.9 ml foetal bovine serum (FBS) and 0.1 ml of 
DMSO, stored at -80°C overnight, and then transferred to liquid nitrogen for use at a later 
stage.  
 
2.7. Proliferation Arrest of Prostatic Cells by 5- dihydrotestosterone (DHT) 
 
To confirm the androgen dependence status of the cell lines used in this study, their 
sensitivity to androgen treatment was determined. For this, 8000-10000 cells were 
seeded in 24-well multiwell plates with medium containing charcoal-stripped foetal 
bovine serum (csFBS). By stripping of serum with activated carbon, steroid 
hormones, specifically 5-dihydrotestosterone (5-DHT), endogenous hormones, 
growth factors and cytokines are removed. This, thus, enables the in vitro evaluation 
of the effects of steroid hormones by addition of 5-DHT to cell cultures. The 
medium for 1542N cell line was supplemented with 0.5% csFBS, the BPH-1 cell line 
with 10% csFBS, and 5% csFBS for the LNCaP cell line, which served as the 
positive control.  5-DHT was added a day later (2 days later in the case of LNCaP) 
in concentrations ranging from 0.001–10 nM, for a period of 4 days.  The experiment 
was stopped after 4 days and the cell growth determined by crystal violet assay, as 
described by Baker and colleagues (Baker et al., 1986). Two control flasks were set 
up, one with charcoal-stripped FBS and one with non-stripped FBS.  The optical 
Stellenbosch University https://scholar.sun.ac.za
31 
 
density (OD) readings, expressed as a percentage of the OD of the positive controls 
(cultures with non-stripped FBS), were plotted against concentrations of DHT.  
 
2.8. Irradiation of Cell Cultures 
 
Cell lines grown in 25 cm2 tissue culture flasks were irradiated using a Precision 
MultiRad 160 X-irradiator (Precision X-Ray Inc., Branford, CT, USA) at the Division 
of Radiobiology (Faculty of Medicine and Health Sciences, Stellenbosch University). 
The X-ray energy and tube current were 130 kV and 23 mA, respectively. Samples 
were irradiated at a source-to-sample distance of 65 cm, measured to the base of 
the experimental flasks, at a dose rate of 1.0 Gy/min. Build-up consisted of 5 ml or 
10 ml (depending on experimental set-up) of medium in the flasks. For all assays cell 
cultures were irradiated at room temperature (22°C). 
 
2.9. Cell Survival Assay and Radiosensitivity 
 
Intrinsic radiation response in all cell lines was measured by clonogenic assay. Near-
confluent stock cultures in exponential growth phase were trypsinised to give single-
cell suspensions and counted using a haemocytometer. Cells were seeded in 
triplicate per experiment in 25 cm2 culture flasks (Greiner, Germany; # 690160) at 
varying densities ranging from 300 to 100 000 cells per flask, depending on cell type, 
and absorbed radiation dose, and left to attach for 4–5 hours. The PCa cell lines 
have relatively low plating efficiencies of ~15-35%. It was, thus, necessary to plate 
high numbers of cells in order to obtain appropriate numbers of colonies. The cell 
cultures were then exposed to radiation doses ranging from 0-10 Gy and incubated 
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at 37ºC for 10-14 days, depending on the cell line. The colonies were fixed, stained 
with Amido Black, and air-dried before counting, using a stereoscopic microscope 
(Nikon, Japan; Model # SMZ-1B), and corresponding surviving fractions calculated. 
The means (± SD) of the surviving fractions (SF) for the three experiments were 
plotted against irradiation dose, and cell survival curves obtained by fitting the data 
to the linear-quadratic equation: 
 
SF= exp[-αD-βD2]                                  (2.1), 
  
where α and β are the linear and quadratic cell inactivation constants, respectively, 
and D is the dose in Gy. Cellular radiosensitivity was expressed in terms of the 
surviving fraction at 2 Gy (SF2), surviving fraction at 6 Gy (SF6), absorbed dose for 
50% cell killing (D50), and mean inactivation dose (?̅?). ?̅? is the area under the cell 
survival curve and depicts radiosensitivity over low-high doses.  
 
2.10. Target Inhibitor Toxicity Measurements 
 
To assess the influence of the inhibitor concentration on cytotoxicity, single-cell 
suspensions were seeded (600-100,000 cells per flask, depending on cell line) into 
25 cm2 culture flasks, and incubated for 3-4 h to allow the cells to attach. The cells 
were exposed to their respective inhibitors; NVP-BEZ235 (0.001-1,000 nM), AG-
1478 (1-100,000 nM) and MDV3100 (10–100 nM), and incubated for 7-10 days for 
colony formation. The colonies were fixed, stained, washed in tap water, air-dried 
and counted. To determine the equivalent concentration of each inhibitor for 50% cell 
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kill (EC50), the surviving fractions (SF) were plotted as a function of log (inhibitor 
concentration) and fitted to a 4-parameter logistic equation of the form: 
 
𝑆𝐹 = 𝐵 +
𝑇−𝐵
{1−10[(𝑙𝑜𝑔𝐸𝐶50−𝐷)𝐻𝑆}
    (2.2), 
 
where B and T are the minimum and maximum of the sigmoidal curve, respectively, 
D is the log (Inhibitor concentration), and HS is the steepest slope of the curve. For 
each cell line and dose point, three independent experiments were performed. 
 
2.11. Evaluation of Therapeutic Potential 
 
To assess whether the various treatment protocols (X-rays or inhibitors) used in this 
study had a potential therapeutic benefit, a relative sensitivity (RS) was determined. 
For this, the D50 and EC50 of the normal cell lines (1542-NPTX) were compared with 
those for the respective tumour cell lines (LNCaP, BPH-1, DU145), as follows 
(Maleka et al., 2019):  
 
𝑅𝑆 =
𝐷50(𝑛𝑜𝑟𝑚𝑎𝑙)
𝐷50(𝑡𝑢𝑚𝑜𝑢𝑟)
  𝑜𝑟 
𝐸𝐶50(𝑛𝑜𝑟𝑚𝑎𝑙)
𝐸𝐶50(𝑡𝑢𝑚𝑜𝑢𝑟)
      (2.3). 
 
The criteria for no potential benefit with possible undesirable effects, no potential 
benefit, and potential therapeutic benefit of each agent, are RS < 1.0, RS = 1.0 and 
RS > 1.0, respectively. 
 
 
  
Stellenbosch University https://scholar.sun.ac.za
34 
 
2.12. Determination of Radiosensitivity Modification by Target Inhibitors 
 
The effect of inhibitor exposure on radiosensitivity was investigated.  Attached cells 
were treated with their respective inhibitors: 1542N (400 nM of AG-1478 and 53.82 
nM of NVP-BEZ235 or 21.36 nM MDV3100); DU145 (6613 nM of AG-1478 and 
16.25 nM of NVP-BEZ235 or 22.43 nM MDV3100); LNCaP (302 nM of AG-1478 and 
6.10 nM of NVP-BEZ235 or 183.2 MDV3100) and BPH-1 (677 nM of AG-1478 and 
6.11 nM of NVP-BEZ235 or 20.35 MDV3100). For each experiment, sets of cell 
culture flasks given inhibitors alone (singly and in combination) were immediately 
irradiated with 2, 4, 6, 8 or 10 Gy, clinically used doses per fraction, in conventional 
and hypofractionated radiotherapy, respectively. Unirradiated flasks, without 
inhibitors, served as Controls for cultures irradiated with and without inhibitors, 
respectively, or a cocktail of both inhibitors at the same concentration. Inhibitor-
treated cell cultures were used as Controls for those receiving inhibitors and 
irradiation to allow for inter-experimental variations in inhibitor toxicity, as exposures 
to predetermined concentrations do not always yield the expected cell kill. The 
interaction between inhibitors and irradiation was expressed as a modifying factor 
(MFsurvival), given as the ratio of surviving fractions at a dose of X-rays (or the mean 
inactivation dose, ?̅?) in the absence and presence of inhibitor: 
 
𝑀𝐹𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 =
𝑆𝐹(𝑋−𝑟𝑎𝑦𝑠)
𝑆𝐹(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟+𝑋−𝑟𝑎𝑦𝑠)
  𝑜𝑟 
?̅?(𝑋−𝑟𝑎𝑦𝑠)
?̅?(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟+𝑋−𝑟𝑎𝑦𝑠)
       (2.4). 
 
The criteria for inhibition, no effect, and enhancement of radiosensitivity by inhibitors 
are MF<1.0, MF=1.0, and MF>1.0, respectively.  
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2.13. Inhibitor Interaction 
 
To test for potential interaction between inhibitors, the toxicity data obtained in 
Section 2.10 were fitted to the function:  
 
log(fa/fu) = m×log(D) – m×log(Dm)   (2.5), 
 
where fa and fu are the affected and unaffected fractions of cells, respectively, to 
generate median-effect plots for each inhibitor. D is the concentration of inhibitor, Dm 
is the median-effect concentration of inhibitor, and the coefficient m is an indicator of 
the shape of the inhibitor concentration-effect relationship (Chou, 2006; Hamunyela 
et al., 2017). The shape parameter m = 1, >1, and <1 are for hyperbolic, sigmoidal, 
and flat-sigmoidal inhibitor concentration-effect curves, respectively. 
 
The mode of interaction between any two inhibitors was assessed by determining 
combination indices (CI) for each inhibitor cocktail from the fitted parameters of 
equation (2.3) according to the equation: 
 
𝐶𝐼 =
𝐷1
{𝐷𝑚1×(
𝑓𝑎1
1−𝑓𝑎1
)
1
𝑚1}
+  
𝐷2
{𝐷𝑚2×(
𝑓𝑎2
1−𝑓𝑎2
)
1
𝑚2}
   (2.6), 
 
 where D1 is the concentration of Inhibitor 1 and D2 is the concentration of Inhibitor 2. 
m1 and m2 are the respective shape parameters. fa1 and fa2 are given as: (1 – SF, as 
defined in equation (2.2)). Dm1 and Dm2 are the corresponding median-effect 
concentrations. Synergism, additivity, and antagonism are indicated by CI < 1, CI = 
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1, and CI > 1, respectively. Furthermore, the criteria for very strong synergism, 
strong synergism, and synergism are CI < 0.1, 0.1 ≤ CI ≤ 0.3, 0.3 < CI ≤ 0.7, 
respectively (Chou, 2006). 
 
2.14. Data Analysis 
 
The GraphPad Prism computer programme (GraphPad Software, San Diego, CA, 
USA) was used to perform statistical analyses. For associations, linear regression 
analyses were used. Standard equations were used to fit nonlinear relationships. 
Data were presented as the mean ± standard error of the mean (SEM) of three 
independent experiments, as indicated by error bars. For each experiment and data 
point, 3 replicates were assessed. To compare two data sets, the unpaired t-test was 
used. P-values were calculated from two-sided tests. A P-value of <0.05 indicated a 
statistically significant difference between the data sets.  
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CHAPTER 3: RESULTS 
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3.1. Androgen Sensitivity of DU145, LNCaP, BPH-1, and 1542N Cells 
 
The crystal violet vital dye staining assay showed that when the DU145 cells were 
grown in medium with charcoal-stripped foetal bovine serum (csFBS), cell 
proliferation decreased by about 35% (Figure 3.1), indicating dependence on 
essential growth factors including androgen and other hormones. Addition of 5-
dihydrotestosterone (5-DHT), at concentrations of 0.001 to 1.0 nM, appeared to 
induce a further concentration-dependent reduction in cell proliferation, but the 
decrease in proliferation was not statistically significant (P = 0.2433). The rate of 
proliferation at 1.0 nM was found to be approximately half the rate in cultures treated 
with medium containing non-stripped FBS. However, at higher 5-DHT 
concentrations (10 and 100 nM), cell proliferation recovered to levels comparable 
with those in non-stripped FBS cultures.  
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Figure 3.1: The effect of 5-dihydrotestosterone (DHT) addition to medium with charcoal stripped 
foetal bovine serum (csFBS) on the proliferation of DU145 cells, measured by crystal violet dye 
staining assay. 
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Growing the LNCaP cells in csFBS containing medium resulted in a 38% reduction in 
cell proliferation (Figure 3.2). When grown in csFBS containing medium, spiked with 
5-DHT, a clear 5-DHT concentration-dependent increase in proliferation emerged, 
indicating dependence of these cells on androgen availability.  
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Figure 3.2: The effect of 5-dihydrotestosterone (DHT) addition to medium with charcoal stripped 
foetal bovine serum (csFBS) on the proliferation of LNCaP cells, measured by crystal violet dye 
staining assay. 
 
 
As expected, depriving the BPH-1 cells of essential growth factors when they were 
grown in medium supplemented with charcoal-stripped FBS, led to a 34% reduction 
in proliferation (Figure 3.3). Adding 5-DHT at concentrations ranging between 0.001 
and 100 nM did not result in a recovery in cell proliferation, indicating that the BPH-1 
cell are insensitive to androgen treatment.  
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Figure 3.3: The effect of 5-dihydrotestosterone (DHT) addition to medium with charcoal stripped 
foetal bovine serum (csFBS) on the proliferation of BPH-1 cells, measured by crystal violet dye 
staining assay. 
 
Interestingly, when the apparently normal 1542N cells were grown in medium 
supplemented with csFBS, a less than 20% reduction in proliferation was observed 
(Figure 3.4). As in the case of the DU145 cells, treatment of the 1542N cells with 5-
DHT (0.001 to 0.1 nM) resulted in an additional concentration-dependent reduction in 
proliferation, reaching a minimum of ~66% at 0.1 nM. However, the decrease in cell 
proliferation did not reach statistical significance (P = 0.3558). Exposure of cells to 
higher concentrations of 5-DHT led to complete recovery in proliferation. 
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Figure 3.4: The effect of 5-dihydrotestosterone (DHT) addition to medium with charcoal stripped 
foetal bovine serum (csFBS) on the proliferation of 1542N cells, measured by crystal violet dye 
staining assay. 
 
 
 
3.2. Intrinsic Radiosensitivity of 1542N, BPH-1, DU145, and LNCaP Cell Lines 
 
Cell survival data for the human prostate carcinoma and normal cell lines (1542N, 
BPH-1, DU145, and LNCaP) were fitted to the linear-quadratic model, and the 
corresponding dose-response curves are presented in Figure 3.5.  
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Figure 3.5: Clonogenic cell survival curves for 4 human prostate cell lines [DU145 (●), LNCaP (□), 
BPH-1 (▲), 1542N (■)] after X-ray irradiation. Survival curves were obtained by fitting experimental 
data to the linear-quadratic model. Symbols represent the mean surviving fraction  SEM from 3 
independent experiments. The dose at which 50% of cells survive (D50) is the dose at which each 
survival curve intersects the horizontal dashed line.   
 
Intrinsic cellular radiosensitivity was expressed in terms of the surviving fraction at 2 
Gy (SF2), surviving fraction at 6 Gy (SF6), radiation dose at which a cell survival of 
50% (50% cell killing) was obtained (D50), and mean inactivation dose (?̅?). The 
radiosensitivity parameters are summarised in Table 3.1.  
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Table 3.1: Summary of radiobiological parameters for the 1542N, BPH-1, DU145, and LNCaP cell 
lines. SF2 and SF6 denote the surviving fraction at 2 and 6 Gy, respectively. α and β are the linear and 
quadratic coefficients of cell inactivation, respectively. ?̅? denotes the mean inactivation dose (area 
under the cell survival curve). D50 the radiation absorbed dose for 50% cell killing. Data are presented 
as the mean ± SEM from 3 independent experiments. 
 
 
In terms of (?̅?), the benign prostatic hyperplasia cell line was found to the most 
radiosensitive, with a mean inactivation dose of 1.94  0.54 Gy. The DU145 cell line 
emerged as the most radioresistant, with a mean inactivation dose of 3.19  0.38 Gy. 
The rank order of radioresistance in the cell lines was found to be BPH-
1<1542N<LNCaP<DU145. On the other hand, when D50 is considered, the 
androgen-dependent cell line, LNCaP, emerged as more radiosensitive than its 
androgen-independent counterparts (1542N, BPH-1, DU145). The rank order of 
radioresistance in the cell lines was found to be LNCaP<1542N<BPH-1<DU145, with 
D50-values of 0.93  0.19, 1.53  0.32, 1.65  0.36, and 2.25  0.54 Gy, respectively. 
No statistically significant differences emerged between the radiosensitivity (based 
on ?̅?  and D50) of the normal cell line when compared with those of the tumour cell 
lines (0.1353  P  0.7893). Given the inconsistency in radiosensitivity ranking when 
a single radiobiological parameter is used, it is necessary to consider using multiple 
Cell Line SF2 SF6 ?̅? (Gy) D50 (Gy) α (Gy-1) β (Gy-2) 
DU145 0.53±0.10 0.13±0.04 3.19±0.38 2.25±0.54 0.28±0.06 0.01±0.01 
LNCaP 0.19±0.04 0.01±0.01  2.52±0.19 0.93±0.19 0.78±0.24 0.02±0.02 
BPH-1 0.40±0.07 0.03±0.01 1.94±0.14 1.65±0.36 0.39±0.05 0.04±0.01 
1542N 0.39±0.10 0.07±0.04 2.09±0.74 1.53±0.32 0.49±0.11 0.00±0.00 
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parameters to obtain a more representative reflection of relative cellular 
radiosensitivity. For this, a rank order was constructed based on SF2, SF6, D50, and 
𝐷,̅  as presented in Table 3.2. Using the frequency of occurrence of each cell line 
under each rank, the cell lines may be arranged in order of increasing radiosensitivity 
as: DU145  BPH-1  1542N  LNCaP.  
 
 
Table 3.2: Summary of relative radiosensitivity of DU145, BPH-1, LNCaP, and 1542N cell lines based 
on SF2, SF6, D50, and ?̅?. 
 
 
 
 
 
 
 
 
 
 
To determine whether treatment of the prostate tumour cell lines with X-rays has a 
potential therapeutic benefit, the relative sensitivities (RS), as described in Section 
2.11, were determined on the basis of the D50-values.  The data presented in Table 
3.3 summarise the relative radiosensitivities of the tumour cells. The absence of 
significant differences between the radiosensitivity of the apparently normal cell line 
and its tumour counterparts translates to relative sensitivities (RS) that do not differ 
significantly from unity, indicating no potential therapeutic benefit.   
 
Parameter Increasing Radiosensitivity  
SF2 DU145 BPH-1 1542N LNCaP 
SF6 DU145 1542N BPH-1 LNCaP 
D50 DU145 BPH-1 1542N LNCaP 
?̅? DU145 LNCaP 1542N BPH-1 
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Table 3.3: Summary of D50-values for 4 human prostate cell lines (normal: 1542N; cancer: DU145, 
LNCaP; benign prostate hyperplasia: BPH-1) and their relative radiosensitivities (RS) determined by 
clonogenic cell survival after exposure to X-rays (Equation 2.3). The 95% confidence intervals of the 
D50-values are in parentheses. P-value indicates the level of significance in the difference between 
the D50 of the normal cell line (1542N) relative to those of the tumour cell lines (DU145, LNCaP, BPH-
1). 
 
 
 
 
 
 
 
 
 
 
 
*Errors were calculated using error propagation formulae for ratios. 
 
 
3.3. Inhibitor Cytotoxicity  
 
3.3.1. Cytotoxicity of EGFR Inhibitor (AG-1478) 
 
Figure 3.6 shows that the EGFR inhibitor (AG-1478) exhibits a concentration-
dependent toxicity in all cell lines, and sensitivity to inhibitor treatment was 
expressed in terms of equivalent concentration for 50% cell killing (EC50) as the 
mean (SEM). Treatment with AG-1478 yielded the same sensitivity ranking, as 
Cell Line D50 (Gy) P-value RS* 
1542N 1.41 ± 0.53 
(0.00 - 3.01) 
− − 
DU145 2.25 ± 0.54 
(0.59 - 3.90) 
0.1932 0.63 ± 0.28 
LNCaP 0.93 ± 0.19 
(0.37 - 1.50) 
0.2935 1.52 ± 0.64 
BPH-1 1.65 ± 0.36 
(0.57 - 2.73) 
0.6214 0.85 ± 0.37 
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observed for X-ray exposure (Figure 3.5), with the LNCaP showing more sensitivity 
than the other cell lines.  
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Figure 3.6: Cytotoxicity curves for EGFR inhibitor (AG-1478) treatment of 4 human prostate cell lines 
(DU145, 1542N, LNCaP, BPH-1). Curves were obtained by plotting cell survival as a function of log 
(inhibitor concentration). Cell survival was determined by the colony assay, and data were fitted to a 
sigmoidal equation. Data points are means ± SEM of 3 independent experiments. The log of the 
concentration at which 50% of cells survive (EC50) is that at which each survival curve intersects the 
horizontal dashed line (as indicated by red arrow). 
 
The EC50 of the normal cell line (1542N) emerged as 416  46 nM and was 
significantly lower than those of the DU145 (7431  1052 nM, P = 0.0402, R2 = 
0.6915) and BPH-1 (708  60 nM, P = 0.0055, R2 = 0.8815) cell lines (Table 3.4). 
The EC50 of the relatively more sensitive LNCaP cell line did not differ significantly 
from that of the 1542N cell line (290   31 nM, P = 0.0783, R2 = 0.5805).  
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3.3.2. Cytotoxicity of PI3K and mTOR Inhibitor (NVP-BEZ235) 
 
Inhibition of PI3K and mTOR inhibitor with NVP-BEZ235 also resulted in a 
concentration-dependent cell killing, as shown in Figure 3.7. The rank order of 
resistance to NVP-BEZ235 treatment is BPH-1 ≈ LNCaP < DU145 < 1542N, with 
EC50-values of 6.26  0.59, 6.42  0.74, 16.49  2.97, and 51.33  11.81 nM, 
respectively. All tumour cell lines were significantly more sensitive to NVP-BEZ235 
treatment than the normal cell line, as shown in Table 3.4 (P  0.0047).  
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Figure 3.7: Cytotoxicity curves for PI3K and mTOR inhibitor (NVP-BEZ235) treatment of 4 human 
prostate cell lines (DU145, 1542N, LNCaP, BPH-1). Curves were obtained by plotting cell survival as 
a function of log (inhibitor concentration). Cell survival was determined by the colony assay, and data 
were fitted to a sigmoidal equation. Data points are means ± SEM of 3 independent experiments. The 
log of the concentration at which 50% of cells survive (EC50) is that at which each survival curve 
intersects the horizontal dashed line (as indicated by red arrow). 
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3.3.3. Cytotoxicity of Androgen Receptor Inhibitor (MDV3100) 
 
The cytotoxicity of the androgen receptor inhibitor (MDV3100) was also 
concentration-dependent, as illustrated in Figure 3.8. The LNCaP cell line was 
significantly more resistant to androgen receptor inhibition that the rest of the cell 
lines (P  0.0008), which were similarly sensitive to MDV3100 treatment. The rank 
order of increasing sensitivity to MDV3100 treatment is LNCaP  1542N ≈ BPH-1 ≈ 
DU145, with EC50-values of 92.73  10.55, 16.92  0.87, 16.64  1.20, and 15.74  
0.94 nM, respectively (Table 3.4).  
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Figure 3.8: Cytotoxicity curves for PI3K and mTOR inhibitor (MDV3100) treatment of 4 human 
prostate cell lines (DU145, 1542N, LNCaP, BPH-1). Curves were obtained by plotting cell survival as 
a function of log (inhibitor concentration). Cell survival was determined by the colony assay, and data 
were fitted to a sigmoidal equation. Data points are means ± SEM of 3 independent experiments. The 
log of the concentration at which 50% of cells survive (EC50) is that at which each survival curve 
intersects the horizontal dashed line (as indicated by red arrow). 
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Table 3.4: Summary of cytotoxicity data for 2 human prostate cancer cell lines (DU145 and LNCaP), 
a benign prostatic hyperplasia cell line (BPH-1), and normal prostate cell line (1542N) treated with 
EGFR inhibitor (AG-1478), PI3K and mTOR inhibitor (NVP-BEZ235), and AR inhibitor (MDV3100). 
EC50 denotes the equivalent concentration for 50% cell survival. T and B are the maximum and 
minimum of the concentration-response curve, respectively (Figures 3.6-3.8). HS is the steepest 
slope of the curve. 
 
 
 
To evaluate the existence of a potential therapeutic benefit when the prostate tumour 
cell lines are treated with the specified inhibitors, relative sensitivities (RS), as 
described in Section 2.11, were determined on the basis of the EC50-values.  The 
data presented in Table 3.5 summarise the relative sensitivities of the tumour cells.  
Cell line Treatment EC50 (nM)  T B HS 
 
DU145 
AG-1478 7431±1052 0.98±0.02  -0.03±0.03 -0.84±0.08  
NVP-BEZ235 16.49±2.97 1.02±0.02 -0.08±0.05 -0.80±0.08 
MDV3100  15.74±0.94  1.01±0.01  -0.02±0.01  -1.22±0.08  
 
LNCaP 
AG-1478 290±31  1.02±0.02  0.03±0.02  -1.07±0.11  
NVP-BEZ235 6.42±0.74 0.99±0.01 -0.03±0.02 -0.91±0.08 
MDV3100  92.73±10.55 1.00±0.02  -0.10±0.04  -0.84±0.07  
 
BPH-1 
AG-1478 708±60 1.03±0.01  -0.02±0.01 -0.83±0.05 
NVP-BEZ235 6.26±0.59 0.99±0.02 -0.03±0.02 -1.02±0.09 
MDV3100 16.64±1.20 1.01±0.02  -0.02±0.02  -1.23±0.11  
 
1542N 
AG-1478 414±46 1.01±0.02  0.01±0.01  -1.02±0.10  
NVP-BEZ235 51.33±3.81    0.98±0.02 -0.16±0.09 -0.79±0.11 
MDV3100  16.92±0.87 0.98±0.01  -0.01±0.01  -1.92±0.17  
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Table 3.5: Summary of EC50-values for 4 human prostate cell lines (normal: 1542N; cancer: DU145, 
LNCaP; benign prostate hyperplasia: BPH-1) and their relative radiosensitivities (RS) determined by 
clonogenic cell survival after exposure to X-rays (Equation 2.3). The 95% confidence intervals of the 
EC50-values are in parentheses. P-value indicates the level of significance in the difference between 
the EC50 of the normal cell line (1542N) relative to those of the tumour cell lines (DU145, LNCaP, 
BPH-1). 
 
*Errors were calculated using error propagation formulae for ratios. 
 
For EGFR inhibition (using AG-1478), the absence of a statistically significant 
difference in EC50 of the relatively more sensitive LNCaP cell line from that of the 
1542N cell line resulted in a relative sensitivity of  1.43  0.22 (Table 3.5), indicating 
a positive but limited therapeutic benefit. The markedly high resistance to EGFR 
Cell line Treatment EC50 (nM) P-value RS* 
 
1542N 
AG-1478 414±46 (330-518) -  -  
NVP-BEZ235 51.33±3.81 (32.32-81.53)     - - 
MDV3100  16.92±0.87 (15.24-18.78) -  -  
 
DU145 
AG-1478 7431±1052 (5554-9943) 0.0402 0.06±0.01  
NVP-BEZ235 16.49±2.97 (11.82-24.07) 0.0047 3.11±0.61 
MDV3100 15.74±0.94 (13.93-17.78) 0.9250  1.08±0.08  
 
LNCaP 
AG-1478 290±31 (233-360)  0.0783  1.43±0.22 
NVP-BEZ235 6.42±0.74 (5.09-8.10) <0.0001 8.00±1.10 
MDV3100  92.73±10.55 (73.59-116.80) <0.0001  0.18±0.02 
 
BPH-1 
AG-1478 708±60 (596-841) 0.0055 0.59±0.08 
NVP-BEZ235 6.26±0.59 (5.15-7.59) 0.0004 8.20±0.98 
MDV3100 16.64±1.20 (14.36-19.27) 0.9377  1.02±0.09   
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inhibitions exhibited by the DU145 and BPH-1 cell lines resulted in very low relative 
sensitivities of 0.06  0.01 and 0.59  0.08, respectively.  
 
In the case of inhibition of PI3K and mTOR (using NVP-BEZ235), the tumour cell 
lines, DU145, LNCaP, and BPH-1, were found to be 3- to 8-fold more sensitive than 
the normal cell line (1542N) with relative sensitivities of 3.11  0.61, 8.00  1.10, and 
8.2  0.98, respectively (Table 3.5).  
 
The sensitivity of the normal cell line (1542N) to androgen receptor (AR) inhibition 
(using MDV3100) was comparable to those of the DU145 and BPH-1 cell lines. This 
translated to relative sensitivities that do not differ from unity (Table 3.5). However, 
the LNCaP cell line emerged as highly resistant to AR inhibition, giving a relative 
sensitivity of 0.18 ± 0.02.  
 
3.4. Mode of Inhibitor Action in Cells  
 
To determine the nature of cellular response to treatment with the EGFR, PI3K and 
mTOR, and AR inhibitors, the cell survival data presented in Figures 3.6-3.8 were log 
transformed as described in Section 2.13, to obtain median-effect plots for the 
inhibitors.  
 
Figure 3.9 represents the median-effect plots for the DU145 cell line. The curves for 
EGFR and PI3K/mTOR inhibition are virtually parallel, with slopes of 0.78 and 0.73, 
respectively (Table 3.6; m < 1.0), indicating flat-sigmoidal concentration-effect 
curves. The median-effect concentrations (Dm) of AG-1478 and NVP-BEZ235 were 
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low, and emerged as 13.28 and 14.27 nM. On the other hand, androgen receptor 
inhibition in these cells yielded a much steeper curve with a slope of 1.63 (m > 1.0), 
indicating a sigmoidal response. The corresponding median-effect concentration of 
MDV3100 was ~370-fold higher than those of AG-1478 and NVP-BEZ235 (Table 
3.6). 
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Figure 3.9: Median-effect plots for DU145 cells treated with AG-1478, NVP-BEZ235 and MDV3100 
from the toxicity data presented in Figures 3.6 – 3.8. Transformed cell survival data were fitted to the 
function: log(fa/fu) = m×log(D) – m×log(Dm), where fa and fu are the affected and unaffected fractions of 
cells, respectively (Section 2.13). The coefficient m is an indicator of the shape of the inhibitor 
concentration-effect relationship. D and Dm are the concentration and median-effect concentration of 
the inhibitor.  
 
 
Figure 3.10 shows the concentration-effect curves for the three inhibitors in the 
LNCaP cell line. Here, the curves for the PI3K/mTOR and androgen receptor 
inhibition are parallel and emerge with slopes of 0.81 and 0.83, respectively (Table 
3.6; m < 1.0), implying that NVP-BEZ235 and MDV3100 display flat-sigmoidal 
cytotoxic effects in the LNCaP cell population. The corresponding median-effect 
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concentrations were 4.47 and 68.19 nM. Inhibition of EGFR in these cells with AG-
1478 resulted in a steeper curve (m = 1.27), indicating a sigmoidal cytotoxic 
response. The median-effect concentration of AG-1478 in the LNCaP cell line was 
368 nM. 
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Figure 3.10: Median-effect plots for LNCaP cells treated with AG-1478, NVP-BEZ235 and MDV3100 
from the toxicity data presented in Figures 3.6 – 3.8. Transformed cell survival data were fitted to the 
function: log(fa/fu) = m×log(D) – m×log(Dm), where fa and fu are the affected and unaffected fractions of 
cells, respectively (Section 2.13). The coefficient m is an indicator of the shape of the inhibitor 
concentration-effect relationship. D and Dm are the concentration and median-effect concentration of 
the inhibitor.  
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Table 3.6:  Summary of parameters of median-effect plots for EGFR inhibitor (AG-1478), PI3K and 
mTOR inhibitor (NVP-BEZ235), and AR inhibitor (MDV3100) in 2 human prostate cancer cell lines 
(DU145 and LNCaP), a benign prostatic hyperplasia cell line (BPH-1), and normal prostate cell line 
(1542N).  
 
 
 
PI3K/mTOR and androgen receptor inhibition in the BPH-1 cell line resulted in a 
sigmoidal cytotoxic response, giving shape parameters of 1.22 and 1.54, 
respectively (Figure 3.11; Table 3.6). The respective median-effect concentrations 
were found to be 4.31 and 14.14 nM. Inhibition of EGFR in BPH-1 cells yielded a flat-
Cell line Treatment m  Dm (nM) Shape of 
concentration-
effect curve 
 
DU145 
AG-1478 0.78 ± 0.06  5162 ± 3  flat-sigmoidal 
NVP-BEZ235 0.73 ± 0.07 13.28 ± 0.46 flat-sigmoidal 
MDV3100  1.63 ± 0.10 14.27 ± 0.27 sigmoidal 
 
LNCaP 
AG-1478 1.27 ± 0.11  368 ± 2  sigmoidal 
NVP-BEZ235 0.81 ± 0.07 4.47 ± 0.17 flat-sigmoidal 
MDV3100  0.83 ± 0.05 68.19 ± 0.62 flat-sigmoidal 
 
BPH-1 
AG-1478 0.95 ± 0.06  760 ± 2  flat-sigmoidal 
NVP-BEZ235 1.22 ± 0.13 4.31 ± 0.17 sigmoidal 
MDV3100  1.54 ± 0.13 14.14 ± 0.40 sigmoidal 
 
1542N 
AG-1478 1.00 ± 0.08 517 ± 2 hyperbolic 
NVP-BEZ235 0.67 ± 0.06    41.82 ± 0.74   flat-sigmoidal 
MDV3100  1.70 ± 0.13 11.35 ± 0.30 sigmoidal 
Stellenbosch University https://scholar.sun.ac.za
55 
 
sigmoidal response, with shape parameter of 0.95 and a resulting median-effect 
concentration of AG-1478 of 760 nM.  
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Figure 3.11: Median-effect plots for BPH-1 cells treated with AG-1478, NVP-BEZ235 and MDV3100 
from the toxicity data presented in Figures 3.6 – 3.8. Transformed cell survival data were fitted to the 
function: log(fa/fu) = m×log(D) – m×log(Dm), where fa and fu are the affected and unaffected fractions of 
cells, respectively (Section 2.13). The coefficient m is an indicator of the shape of the inhibitor 
concentration-effect relationship. D and Dm are the concentration and median-effect concentration of 
the inhibitor.  
 
 
Inhibition of EGFR, PI3K/mTOR, and AR in the 1542N cell line yielded hyperbolic, 
flat-sigmoidal, and sigmoidal cytotoxic responses, respectively (Figure 3.12). The 
shape parameters for treatment with AG-1478, NVP-BEZ235, and MDV3100 were 
1.0, 0.67, and 1.70, respectively. The corresponding median-effect concentrations 
emerged as 517, 41.82, and 11.35 nM.   
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Figure 3.12: Median-effects plots for 1542N cells treated with AG-1478, NVP-BEZ235 and MDV3100 
from the toxicity data presented in Figures 3.6 – 3.8. Transformed cell survival data were fitted to the 
function: log(fa/fu) = m×log(D) – m×log(Dm), where fa and fu are the affected and unaffected fractions of 
cells, respectively (Section 2.13). The coefficient m is an indicator of the shape of the inhibitor 
concentration-effect relationship. D and Dm are the concentration and median-effect concentration of 
the inhibitor.  
 
 
3.5. Inhibitor Interaction 
 
To evaluate potential interactions between the EGFR, PI3K and mTOR, and AR 
inhibitors in the DU145, LNCaP, BPH-1, and 1542N cell lines, combination indices 
(CI) were determined for two-inhibitor combinations (at EC50 concentrations), as 
described under Section 2.13. The inhibitor-inhibitor interaction data are summarised 
in Table 3.7. Combination of all inhibitors with each other resulted in very strong 
synergism (CI < 0.1) in the DU145 cell line.  
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While antagonism (CI > 1.0) was observed in the LNCaP cell line when the EGFR 
inhibitor (AG-1478) was combined with the PI3K/mTOR inhibitor (NVP-BEZ235) or 
the AR inhibitor (MDV3100), a very strong synergism emerged when cells were 
concomitantly treated with NVP-BEZ235 and MDV3100. 
 
Table 3.7: Summary of combination indices for EGFR inhibitor (AG-1478), PI3K and mTOR inhibitor 
(NVP-BEZ235), and AR inhibitor (MDV3100), when used concurrently at their respective EC50 
concentrations in 2 human prostate cancer cell lines (DU145 and LNCaP), a benign prostatic 
hyperplasia cell line (BPH-1), and normal prostate cell line (1542N).  
 
 
Cell line Agent 1 
Agent 2 
AG-1478    NVP-BEZ235 MDV3100 
 
DU145 
AG-1478 -  0.0082 0.0784 
NVP-BEZ235 0.0082 - 0.0787 
MDV3100  0.0784 0.0787 - 
 
LNCaP 
AG-1478 -  1.1035 1.0830 
NVP-BEZ235 1.1035 - 0.0315 
MDV3100  1.0830 0.0315 - 
 
BPH-1 
AG-1478 -  0.0998 0.0741 
NVP-BEZ235 0.0998 - 0.1591 
MDV3100  0.0741 0.1591 - 
 
1542N 
AG-1478 - 0.0096 0.1095 
NVP-BEZ235 0.0096 - 0.1028 
MDV3100  0.1095 0.1028 - 
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In the BPH-1 cell line, combining AG-1478 with the NVP-BEZ235 or MDV3100 
resulted in a very strong synergism (CI < 0.1). However, concomitant treatment of 
cells with NVP-BEZ235 and MDV3100 was only synergistic (0.1 ≤ CI ≤ 0.3). 
 
Similarly, Combination of all inhibitors with each other in the apparently normal cell 
line (1542N) yielded effects that ranged from strong to very strong synergism (CI < 
0.1). 
 
 
3.6. Radiomodulation by Inhibitors 
 
To investigate the relationship between the fraction of cells retaining their 
reproductive integrity and absorbed radiation doses, and the impact of cellular 
exposure of inhibitors of EGFR (AG-1478), PI3K/mTOR (NVP-BEZ235) and AR 
(MDV3100) on radiosensitivity, the colony forming assay was used. The clonogenic 
cell survival data for the DU145 cell line (the most radioresistant cell line (Table 3.2) 
are presented in Figure 3.13. Pre-treatment with AG-1478, NVP3100, and a cocktail 
of both inhibitors radiosensitised these cells. However, the radiosensitisation by AG-
1478 emerged only at doses higher than 6 Gy, as reflected in the modifying factors 
not differing markedly from unity (Table 3.8). Although the radiosensitisation by NVP-
BEZ235 and the cocktail was high, it did not reach statistical significance, except for 
PI3K/mTOR inhibition when the parameter ?̅? was used. The significant 
radiosensitisation is in line with the strong synergism seen in this cell line between 
these inhibitors (Table 3.7). 
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Figure 3.13: Cell survival curves for the DU145 cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of AG-1478 and NVP-BEZ235, administered either singly or as a cocktail at 
EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. 
 
 
The data presented in Figure 3.14 are the cell survival curves for when PI3K/mTOR 
and AR were inhibited in the DU145 cell line with NVP-BEZ235 and MDV3100, 
singly and in combination. This inhibition resulted in radiosensitation over the entire 
radiation dose range, with modifying factors ranging from 1.20 to 4.33 (Table 3.9). 
Only the radiosensitisation by cocktail pre-treatment, when SF6 and ?̅? were used as 
radiosensitivity parameters, emerged statistically significant with modifying factors of 
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4.33 (P = 0.0339) and 1.37 (P = 0.0422), respectively. This level of radiosensitisation 
seems to be consistent with the strong synergism seen in this the cocktail (Table 
3.7). 
 
Table 3.8: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the DU145 cell line, irradiated in the presence of AG-1478 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
*Statistically significant difference between X-ray treatment alone and irradiation in the presence of 
inhibitor. 
 
  
Treatment Parameter P-value MF 
 SF2   
X-rays 0.53 ± 0.10 - - 
X-rays + AG-1478 0.64 ± 0.19     0.6219 0.83 ± 0.29 
X-rays + NVP-BEZ235  0.37 ± 0.06 0.1500  1.43 ± 0.36 
X-rays + Cocktail 0.42 ± 0.08 0.3775 1.26 ± 0.34  
 SF6   
X-rays 0.13 ± 0.04  -  -  
X-rays + AG-1478 0.12 ± 0.02  0.8012  1.08 ± 0.38 
X-rays + NVP-BEZ235  0.05 ± 0.01  0.0724 2.60 ± 0.95 
X-rays + Cocktail 0.05 ± 0.02  0.1370  2.60 ± 1.31 
 ?̅?   
X-rays 3.19 ± 0.38 - - 
X-rays + AG-1478 2.94 ± 0.32 0.5692 1.09 ± 0.18 
X-rays + NVP-BEZ235  2.34 ± 0.15  0.0489* 1.36 ± 0.18 
X-rays + Cocktail 2.51 ± 0.27  0.1867  1.27 ± 0.20 
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Figure 3.14: Cell survival curves for the DU145 cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of MDV3100 and NVP-BEZ235, administered either singly or as a cocktail 
at EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. 
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Table 3.9: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the DU145 cell line, irradiated in the presence of MDV3100 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
*Statistically significant difference between X-ray treatment alone and irradiation in the presence of 
inhibitor. 
 
 
 
Figure 3.15 displays results for the androgen dependent cell line (LNCaP), which is 
the most radiosensitive cell line according to Table 3.2. In general, pre-treatment of 
Treatment Parameter P-value MF 
 SF2   
X-rays 0.53 ± 0.10 - - 
X-rays +  MDV3100 0.41 ± 0.02 0.1538 1.29 ± 0.25 
X-rays + NVP-BEZ235  0.43 ± 0.02 0.2139  1.23 ± 0.23 
X-rays + Cocktail 0.38 ± 0.06 0.1711 1.39 ± 0.34 
 SF6   
X-rays 0.13 ± 0.04  -  -  
X-rays +  MDV3100 0.08 ± 0.01 0.1538  1.63 ± 0.54 
X-rays + NVP-BEZ235  0.06 ± 0.01  0.0879 2.17 ± 0.76 
X-rays + Cocktail 0.03 ± 0.01  0.0339*  4.33 ± 1.97 
 ?̅?   
X-rays 3.19 ± 0.38 - - 
X-rays +  MDV3100 2.67 ± 0.13 0.1544 1.20 ± 0.15 
X-rays + NVP-BEZ235  2.67 ± 0.09  0.1376 1.20 ± 0.15 
X-rays + Cocktail 2.33 ± 0.12  0.0422*  1.37 ± 0.18 
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these cells with AG-1478, NVP-BEZ235, or their cocktail either had no effect or 
tended to enhance cell survival, as can be deduced from the modifying factors 
presented in Table 3.10. The absence of a significant radiosensitisation by the 
inhibitor cocktail supports the finding that the mode of interaction between AG-1478 
and NVP-BEZ235 in this cell line is antagonistic (Table 3.7).  
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Figure 3.15: Cell survival curves for the LNCaP cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of AG-1478 and NVP-BEZ235, administered either singly or as a cocktail at 
EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. 
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Table 3.10: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the LNCaP cell line, irradiated in the presence of AG-1478 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
*Statistically significant difference between X-ray treatment alone and irradiation in the presence of 
inhibitor. 
 
 
 
 
 
 
 
 
 
Treatment Parameter P-value MF 
 SF2   
X-rays 0.49 ± 0.16 - - 
X-rays + AG-1478 0.36 ± 0.08 0.4159 1.36 ± 0.54 
X-rays + NVP-BEZ235  0.29 ± 0.07 0.2145  1.69 ± 0.69 
X-rays + Cocktail 0.36 ± 0.12 0.4660 1.36 ± 0.64 
 SF6   
X-rays 0.02 ± 0.01  -  -  
X-rays + AG-1478 0.03 ± 0.01 0.5343  0.67 ± 0.40 
X-rays + NVP-BEZ235  0.03 ± 0.01  0.4175 0.67 ± 0.40 
X-rays + Cocktail 0.01 ± 0.01  0.4331  2.00 ± 2.23 
 ?̅?   
X-rays 2.73 ± 0.29 - - 
X-rays + AG-1478 2.26 ± 0.30 0.2703 1.21 ± 0.21 
X-rays + NVP-BEZ235  1.88 ± 0.21  0.0433* 1.45 ± 0.22 
X-rays + Cocktail 2.21 ± 0.20  0.1396  1.24 ± 0.17 
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However, pre-treatment of the LNCaP cells with the androgen receptor inhibitor, 
MDV3100, either alone or in combination with NVP-BEZ235 resulted in enhanced 
radiosensitivity (Figure 3.16). In terms of SF2 and SF6, the modifying factors were 
found to range between 2.72 and 21.30, with the cocktail tending to yield high 
radiosensitisation (Table 3.11). The extent of radiosensitisation seen in the cocktail 
pre-treated cell cultures supports strong synergism between NVP-BEZ235 MDV3100 
(Table 3.7). The modifying factors obtained from ?̅? were lower (Table 3.11).   
 
2 4 6 8 10 120
0.00001
0.0001
0.001
0.01
0.1
1
LNCaP
X-rays
X-rays + MDV3100
X-rays + NVP-BEZ235
X-rays + Cocktail
Absorbed dose (Gy)
S
u
rv
iv
in
g
 f
ra
c
ti
o
n
 
 
Figure 3.16: Cell survival curves for the LNCaP cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of MDV3100 and NVP-BEZ235, administered either singly or as a cocktail 
at EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. 
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Table 3.11: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the LNCaP cell line, irradiated in the presence of MDV3100 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
*Statistically significant difference between X-ray treatment alone and irradiation in the presence of 
inhibitor. 
 
 
 
 
 
 
 
Treatment Parameter P-value MF 
 SF2   
X-rays 0.49 ± 0.16 - - 
X-rays +  MDV3100 0.18 ± 0.07 0.0785 2.72 ± 1.38 
X-rays + NVP-BEZ235  0.39 ± 0.11 0.5580  1.26 ± 0.54 
X-rays + Cocktail 0.12 ± 0.01 0.0298* 4.08 ± 1.37 
 SF6   
X-rays 0.0213 ± 0.0067  -  -  
X-rays +  MDV3100 0.0027 ± 0.0009 0.0506 7.89 ± 3.62 
X-rays + NVP-BEZ235  0.0230 ± 0.0047  0.8487 0.93 ± 0.29 
X-rays + Cocktail 0.0010 ± 0.0001  0.1152  21.30 ± 7.03 
 ?̅?   
X-rays 2.73 ± 0.29 - - 
X-rays +  MDV3100 1.83 ± 0.11 0.0168* 1.49 ± 0.18 
X-rays + NVP-BEZ235  1.88 ± 0.20  0.0399* 1.45 ± 0.22 
X-rays + Cocktail 2.40 ± 0.37  0.4466  1.14 ± 0.21 
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Overall, pre-treatment of the benign prostatic hyperplasia cell line (BPH-1) to NVP-
BEZ235 or a cocktail of NVP-BEZ235 and AG-1478 did not result in a significant 
change in radiosensitivity (Figure 3.17; Table 3.12). However, pre-treatment of these 
cells with AG-1478 alone appeared to lead to enhanced radioresistance, on the 
basis of the mean inactivation dose (Table 3.12). The absence of a marked 
enhancement in radiosensitivity in the cocktail pre-treated cultures does not support 
the strong synergy seen between NVP-BEZ235 and AG-1478 (Table 3.7).  
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Figure 3.17: Cell survival curves for the BPH-1 cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of AG-1478 and NVP-BEZ235, administered either singly or as a cocktail at 
EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. 
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Table 3.12: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the BPH-1 cell line, irradiated in the presence of AG-1478 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
*Statistically significant difference between X-ray treatment alone and irradiation in the presence of 
inhibitor. 
 
 
 
 
 
Treatment Parameter P-value MF 
 SF2   
X-rays 0.40 ± 0.07 - - 
X-rays + AG-1478 0.39 ± 0.06 0.8196 1.03 ± 0.24 
X-rays + NVP-BEZ235  0.29 ± 0.10 0.3718  1.38 ± 0.53 
X-rays + Cocktail 0.40 ± 0.08 0.9944 1.00 ± 0.27 
 SF6   
X-rays 0.03 ± 0.01  -  -  
X-rays + AG-1478 0.04 ± 0.01 0.3869 0.75 ± 0.31 
X-rays + NVP-BEZ235  0.04 ± 0.02  0.6367 0.75 ± 0.45 
X-rays + Cocktail 0.04 ± 0.02  0.4640  0.75 ± 0.45 
 ?̅?   
X-rays 1.94 ± 0.14 - - 
X-rays + AG-1478 2.91 ± 0.06 0.0011* 0.67 ± 0.05 
X-rays + NVP-BEZ235  1.84 ± 0.28  0.7556 1.05 ± 0.18 
X-rays + Cocktail 2.25 ± 0.15  0.1533 0.86 ± 0.08 
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Similar results were obtained when the BPH-1 cells were pre-treated with MDV3100 
or a cocktail of MDV3100 and NVP-BEZ235 (Figure 3.18), and do not reflect the 
synergy demonstrated between these inhibitors (Table 3.7).  
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Figure 3.18: Cell survival curves for the BPH-1 cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of MDV3100 and NVP-BEZ235, administered either singly or as a cocktail 
at EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. 
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Table 3.13: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the BPH-1 cell line, irradiated in the presence of MDV3100 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
 
 
 
 
 
 
 
 
Treatment Parameter P-value MF 
 SF2   
X-rays 0.40 ± 0.07 - - 
X-rays +  MDV3100 0.34 ± 0.06 0.4570 1.18 ± 0.29 
X-rays + NVP-BEZ235  0.39 ± 0.08 0.8570  1.03 ± 0.28 
X-rays + Cocktail 0.26 ± 0.03 0.0640 1.54 ± 0.32 
 SF6   
X-rays 0.03 ± 0.01  -  -  
X-rays +  MDV3100 0.04 ± 0.01 0.4338 0.75 ± 0.31 
X-rays + NVP-BEZ235  0.06 ± 0.02  0.1485 0.50 ± 0.24 
X-rays + Cocktail 0.02 ± 0.01  0.5175  1.50 ± 0.90 
 ?̅?   
X-rays 1.94 ± 0.14 - - 
X-rays +  MDV3100 1.94 ± 0.13 0.9848 1.00 ± 0.10 
X-rays + NVP-BEZ235  2.15 ± 0.17  0.3358 0.90 ± 0.10 
X-rays + Cocktail 2.19 ± 0.31  0.4913  0.89 ± 0.14 
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Pre-treatment of the apparently normal prostate cell line (1542N) with the 
PI3K/mTOR and AR inhibitors, singly or in combination, only seemed to induced 
radiosensitisation at radiation doses higher than 4 Gy (Figure 3.20). In fact, the 
PI3K/mTOR inhibitor (NVP-BEZ235) with showed a radioprotective effect in these 
cells at lower doses. From the modifying factors presented in Table 3.14, no 
significant effect was apparent for all treatment permutations. Again, absence of a 
marked effect in the cocktail pre-treated cultures does not support the strong synergy 
shown between AG-1478 and NVP-BEZ235 (Table 3.7). 
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Figure 3.19: Cell survival curves for the 1542N cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of AG-1478 and NVP-BEZ235, administered either singly or as a cocktail at 
EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments. 
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Table 3.14: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the 1542N cell line, irradiated in the presence of AG-1478 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
 
 
 
 
 
 
Treatment Parameter P-value MF 
 SF2   
X-rays 0.39 ± 0.10 - - 
X-rays + AG-1478 0.34 ± 0.02 0.5568 1.15 ± 0.30 
X-rays + NVP-BEZ235  0.45 ± 0.05 0.4857  0.87 ± 0.24 
X-rays + Cocktail 0.33 ± 0.06 0.5345 1.18 ± 0.37 
 SF6   
X-rays 0.07 ± 0.04  -  -  
X-rays + AG-1478 0.04 ± 0.01 0.3180 1.75 ± 1.09 
X-rays + NVP-BEZ235  0.04 ± 0.01  0.4242 1.75 ± 1.09 
X-rays + Cocktail 0.03 ± 0.01  0.2014  2.33 ± 1.54 
 ?̅?   
X-rays 2.09 ± 0.44 - - 
X-rays + AG-1478 1.59 ± 0.37 0.4769 1.32 ± 0.46 
X-rays + NVP-BEZ235  3.46 ± 0.17 0.0694 0.60 ± 0.13 
X-rays + Cocktail 2.12 ± 0.11  0.9631 0.99 ± 0.21 
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Similarly, pre-treatment of the 1542N cells with MDV3100 or a cocktail of MDV3100 
and NVP-BEZ235 did not result in significant radiomodulatory effects (Figure 3.20; 
Table 3.15). This finding is also not in line with the strong synergism shown between 
MDV3100 and NVP-BEZ235 (Table 3.7).  
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Figure 3.20: Cell survival curves for the 1542N cell line after X-ray irradiation. Cells were irradiated 
without or in the presence of MDV3100 and NVP-BEZ235, administered either singly or as a cocktail 
at EC50 concentrations. Symbols represent the mean surviving fraction ± SEM from three independent 
experiments.  
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Table 3.15: Modifying factors (MF), relative to X-ray treatment alone, derived from SF2, SF6, and ?̅? 
values, as described in Section 2.12 for the 1542N cell line, irradiated in the presence of MDV3100 
and NVP-BEZ235, singly or as a cocktail at EC50 concentrations. Errors in modifying factors were 
calculated using error propagation formulae for ratios.  
 
 
 
 
 
 
Treatment Parameter P-value MF 
 SF2   
X-rays 0.39 ± 0.10 - - 
X-rays +  MDV3100 0.20 ± 0.04 0.0720 1.95 ± 0.63 
X-rays + NVP-BEZ235  0.32 ± 0.07 0.5236  1.22 ± 0.41 
X-rays + Cocktail 0.22 ± 0.06 0.1355 1.77 ± 0.66 
 SF6   
X-rays 0.07 ± 0.04  -  -  
X-rays +  MDV3100 0.01 ± 0.01 0.1274 7.00 ± 8.06 
X-rays + NVP-BEZ235  0.03 ± 0.01  0.2681 2.33 ± 1.54 
X-rays + Cocktail 0.02 ± 0.01  0.1303  3.50 ± 2.66 
 ?̅?   
X-rays 2.09 ± 0.44 - - 
X-rays +  MDV3100 1.53 ± 0.04 0.3414 1.37 ± 0.29 
X-rays + NVP-BEZ235  3.39 ± 0.13  0.0742 0.62 ± 0.13 
X-rays + Cocktail 2.01 ± 0.33  0.9043  1.04 ± 0.28 
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CHAPTER 4: DISCUSSION 
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4.1. Androgen Sensitivity of 1542N, BPH-1, DU145, and LNCaP Cells 
 
Prostate cancer presents itself as a heterogeneous disease (Shah et al., 2004; 
Dicken et al., 2018), meaning the same tumour expresses different genotypes giving 
clinicians a headache in managing the disease, because treatment is not a “one size 
fits all” approach. Conventional therapy still plays a pivotal role in the management of 
PCa, however there is room for improvement as quality of life and survival rate of 
patients is compromised. Targeted therapy has been investigated in the last 3 
decades and promising outcomes have been brought forward (Hurvitz et al., 2013; 
Kratochwil et al., 2016). Interestingly, the biological processes leading to the 
development of PCa might provide the answers in offering tailored medicine. For the 
purpose of this study, the androgen sensitivity of 4 prostate cell lines was 
investigated (DU145, LNCaP, BPH-1, 1542N). As mentioned, PCa is a disease of 
hormones and its progression is driven largely by hormones, and so the majority of 
prostate cancers are androgen dependent (Chen et al., 2008; Ryan and Tindall, 
2011; Jain et al., 2012). Consequently, PCa patients benefit from androgen 
deprivation therapy by surgical or chemical castration, and combination therapy, too, 
has yielded results in recent clinical trials (Thamilselvan et al., 2017; Scott, 2017). 
 
The challenge, then, is the androgen independent stage, where prostate tumour 
growth and survival does not depend on androgens only, but on other avenues, for 
example, the PI3K and EGFR pathways. The molecular basis for the switch from 
androgen dependence to androgen independence in prostate cancer is largely 
unknown and has been under investigation for decades (Tilley et al., 1990; Chen et 
al., 1992; Yuan et al., 1993; Serafin et al., 2001; 2003). However, there is 
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speculation, such as the feedback loop, also known also as “cross talk”, between 
survival pathways (Carracedo and Pandolfi, 2008; Carracedo et al., 2008; Joshi, 
2015). For example, inhibition of AR might activate the (PI3K, mTOR or EGFR), 
increase in proliferation and survival, resulting in castration-resistant prostate cancer 
(CRPC) and hormone-refractory prostate cancer (HRPC) (Lonergan and Tindall, 
2011; Jain et al., 2012). 
 
The androgen sensitivity assay shows that addition of 5-dihydrotestosterone (5-
DHT), at concentrations of 0.001 to 100 nM, to cell culture medium has no significant 
effect on BPH-1 cell growth (Figure 3.3). However, when the LNCaP cells were 
cultured in charcoal-stripped medium, spiked with 5-DHT over the same 
concentration range, proliferation was enhanced and fully restored at 10 nM of 5-
DHT (Figure 3.2). These findings are consistent with those of Serafin et al. 
demonstrating that BPH-1 and LNCaP cell lines are androgen independent and 
dependent, respectively (Serafin et al., 2001). Contrary to the observation that the 
DU145 and 1542N cell lines are androgen independent (Serafin et al., 2001; 2002), 
this study shows that 5-DHT (at 0.001 – 1.0 nM) appeared to inhibit cell 
proliferation in these cell lines (Figures 3.1 and 3.4). Interestingly, at higher 5-DHT 
concentrations (10 – 100 nM), proliferation in the DU145 and 1542N cells recovered 
to normal levels. These results seem to suggest that the DU145 and 1542N cell line 
are not androgen independent as initially thought (Serafin et al., 2001; 2002). In 
other studies by Kaighn and Tilley and colleagues the PC-3 and DU145 cell lines 
were seen to not express an androgen receptor and were, therefore, not dependent 
on androgens for growth (Kaighn et al.,1979; Tilley et al., 1990). The reason for this 
disparity is not known, but the current finding that cell proliferation recovered in the 
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DU145 and 1542N cell lines (Figures 3.1 and 3.4) at 5-DHT concentrations of 10 - 
100 nM, thus linking them to androgen dependence, seems to suggest that 
androgen may have a dual effect on these cells. Does this perhaps suggest that 
these cell lines have switched from an androgen independent status to an androgen 
dependent status? This result could be beneficial, especially for androgen 
independent cancers, which are resistant to treatment, and it would open the door to 
available treatment options. Especially the ADT which is the standard treatment 
protocol for androgen dependent cancers. 
 
As for the LNCaP cell line, defined as androgen dependent, our results concur with 
work done by Serafin and colleagues (Serafin et al; 2002), also with increasing 
concentrations of 5-DHT at 10 to 100 nM, similar results were observed by (Guo et 
al., 2000; Chen et al., 1992). The LNCaP cell line is believed to have a point 
mutation in the ligand-binding domain of the receptor gene, and, hence, is 
responsive to androgens (Veldscholte et al., 1990; 1992). 
 
4.2. Therapeutic Benefit of X-rays and Inhibitors  
 
Using the clonogenic survival assay, it is demonstrated for 4 human prostate cell 
lines that there is no significant therapeutic advantage when D50-values of the 
tumour cell lines (LNCaP, BPH-1, DU145) were compared with that of the apparently 
normal cell line (1542N) (Figure 3.5, Table 3.3). The ranking order, from most 
radiosensitive to least radiosensitive using X-ray irradiation, is LNCaP>1542N>BPH-
1>DU145, and is in close agreement with radiosensitivity data reported previously for 
these cell lines following cobalt-60 -ray exposure (Serafin et al., 2003). The absence 
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of a therapeutic benefit may be explained by the fact that the D50-values are derived 
at 50% cell survival which coincides with the shoulder region of the survival curves, 
and may not differ markedly. For instance, a comparison of doses at the level of 10% 
survival, yields relative sensitivities of 1.77, 1.18, and 0.78, for the LNCaP, BPH-1, 
and DU145 cell lines, respectively, indicating a potential benefit for the former two. 
However, the rationale for choosing D50 and EC50 was to enable comparison of the 
relative sensitivities (RS) of the cell lines at the same level of survival, when as low 
as possible radiation dose or inhibitor concentration is administered. It should also 
be acknowledged that molecular assays have been developed applying multigene 
expression profiles to predict tumour radiosensitivity by comparisons with clonogenic 
survival data from established cell lines (Eschrich et al., 2009; Torres-Roca, 2012), 
that likely have the most potential for clinical implementation. Such methods have 
been shown to be statistically predictive of tumour response in oesophageal and 
rectal cancers, and of locoregional control in head and neck cancers (Eschrich et al., 
2009).  As such, there is the need to explore avenues like the inhibition of EGFR, 
PI3K, and mTOR, described here. 
 
The cytotoxic effects of AG-1478 (EGFR inhibitor), NVP-BEZ235 (PI3K and mTOR 
inhibitor), and MDV3100 (AR inhibitor) are concentration-dependent (Figures 3.6-
3.8). For AG-1478, EC50 values ranged from 290 - 7431 nM (Figure 3.6, Table 3.5), 
giving relative sensitivities of less than 1.0 for the androgen-independent BPH-1 cell 
line (Figure 3.3) and the DU145 cell line in which androgen appears to exert both 
anti- and pro-proliferative effects (Figure 3.1). This clearly shows that the normal 
cells (1542N) are more sensitive to EGFR inhibition than their tumour counterparts 
and use of AG-1478 for treatment of prostate cancer might lead to undesirable 
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outcomes. However, inhibiting EGFR in the androgen-dependent LNCaP cells 
(Figure 3.2) showed a small therapeutic benefit, with a relative sensitivity of 1.52 
(Table 3.5). The significant level of resistance to EGFR inhibition seen in the DU145 
and BPH-1 cell lines (relative sensitivities of 0.06 and 0.59, respectively), relative to 
the LNCaP cell line, is likely due to the fact that EGFR expression in the former is 
over 5-fold that in the latter (Sherwood et al., 1998; El Sheikh et al., 2004; Pignon et 
al., 2009). Higher EGFR expression levels would require significantly larger 
concentrations of inhibitor to achieve a given proportion of cell killing. On the other 
hand, EGFR expression in the androgen-dependent LNCaP cells is low and 
comparable to that in the normal 1542N cells (Hastie et al., 2005), consistent with 
the observed relative sensitivity of 1.43  0.22 (Table 3.5).  
 
For NVP-BEZ235 treatment, EC50 values ranged from 6.26 – 51.33 nM for all cell 
lines (Figure 3.7, Table 3.5), and are consistent with those recently reported for 
human breast cell lines (Hamunyela et al., 2017). Here, the normal cell line (1542N) 
is clearly the most resistant to PI3K and mTOR inhibition, making the tumour cell 
lines 3 to 8 times more sensitive (Table 3.5). This resistance can be attributed to 
NVP-BEZ235 being specifically more toxic to malignant cells, as reported elsewhere 
(McMillin et al., 2009). The sensitivity ranking of the malignant cell lines (DU145 and 
LNCaP) may be related to the extent to which NVP-BEZ235 inhibits the activity of 
key components of the PI3K/mTOR pathway, such as,  PDK1Ser241, AktThr308, 
AktSer473, GSK3Ser19, FoxolaSer256, S6KSer235/236, 4EBP1Thr27/66, and MDM2Ser166. On 
average, inhibition of activity of these components by a dual PI3K/mTOR inhibitor 
(XL765) has been shown to be about 2-fold more effective in the LNCaP cell line 
than the DU145 cell line (Gravina et al., 2015). The clonogenic cell survival data 
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presented here are consistent with this, with the LNCaP cells being 2.6-fold more 
sensitive than the DU145 cells (Table 3.5). However, the similarity in NVP-BEZ235 
cytotoxicity in LNCaP and BPH-1 cells (EC50 of 6.42 ± 0.74 and 6.26 ± 0.59, 
respectively) cannot be corroborated by the finding that NVP-BEZ235 is about 10-
fold less effective in inhibiting cell proliferation than the latter cell line (Gravina et al., 
2015). This disparity is likely due to differences in experimental design and 
endpoints. While the clonogenic cell survival assay described here takes about 2 
weeks and reflects delayed effects of PI3K and mTOR inhibition, the cell growth 
assay of Gravina and colleagues lasts only 24 hours and could miss such effects 
(Gravina et al., 2015). 
 
For MDV3100 treatment, EC50 values ranged from 15.74 – 92.73 nM for all cell lines 
(Figure 3.8; Table 3.5). Here, the androgen dependent cell line (LNCaP) seems to 
the most significantly resistant to MDV3100, with a low relative sensitivity of 0.18. 
Similar resistance to MDV3100 treatment was also seen in CRPC, and LNCaP and 
C4-2 cells (Kuruma et al., 2013; Korpal et al., 2013). Interestingly, the traditional 
androgen-independent cell lines (DU145 and BPH-1) showed higher sensitivity to 
MDV3100 treatment. The rank order of increasing sensitivity to MDV3100 treatment 
is: LNCaP  1542N ≈ BPH-1 ≈ DU145, with EC50-values of 92.73, 16.92, 16.64, and 
15.74 nM, respectively (Table 3.4). The significant level of resistance to MDV3100 
inhibition seen in the LNCaP cell line relative to the 1542N, BPH-1 and DU145 cell 
lines, is likely due to the fact that androgen receptor (AR) expression in the LNCaP is 
higher than androgen independent cell lines (Kuruma et al., 2013; Korpal et al., 
2013). Higher AR expression levels would require significantly larger concentrations 
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of inhibitor to effectively block receptor activity and result in a given proportion of cell 
killing. 
 
Remission of prostate cancer after androgen deprivation therapy (ADT) is usually 
due to the initiation of CRPC. At this stage, tumours grow even when androgen 
levels are low. The central mechanism driving progression of CRPC is AR activation 
(Snoek et al., 2009). However, the question is how this is possible with low levels of 
androgen. Could it be due to AR gene amplification, activation of a promiscuous 
pathway, increase in AR sensitivity, or altered expression of co-regulators (Guo et 
al., 2009; Shiota et al., 2011)? These potential mechanisms are driven by AR 
activation, resulting in CRPC progression (Snoek et al., 2009). Therefore, targeting 
the androgen receptor remains a critical element in investigating novel strategies for 
CRPC therapies (Feldman and Feldman, 2001). 
 
4.3. Inhibitor Interaction  
 
Systemic toxicity experienced by patients that undergo chemotherapy for prostate 
cancer (PCa) is of significant concern in the clinics. Although chemotherapy drugs 
like IMC-C225 (cetuximab), enzalutamide, abiraterone, prednisone, and docetotaxel 
have yielded great results in improving cancer patient survival (Liu et al., 2010; 
Gomez et al., 2015; Silberstein et al., 2016; Byeon et al., 2019; Halfdanarson et al., 
2019), tumour resistance and systemic toxicity remain key challenges. Therefore, 
therapeutic approaches combining a number of agents to achieve optimum 
therapeutic benefit with minimal toxicity have been proposed (Akudugu et al., 2011; 
2012; Pasternack et al., 2014). Furthermore, Hamunyela and colleagues 
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demonstrated that a cocktail of PI3K/mTOR and human epidermal growth factor 
receptor 2 (HER-2) inhibitors radiosensitise breast cancer cells which have shown to 
be resistant to trastuzumab (Hamuneyela et al., 2015). Subsequently, it was 
demonstrated that a strong synergism exists between small molecule inhibitors of 
HER-2, PI3K, mTOR and Bcl-2 in human breast cancer cells (Hamunyela et al., 
2017). In CRPC, a combination of AKT inhibitor (AZD6363) with antiandrogen 
(bicalutamide) resulted in synergistic inhibition of cell proliferation and induction of 
apoptosis (Thomas et al., 2013). Antibody-drug conjugates (ADC) and potent 
antiandrogens (enzalutamide and abiraterone) also yielded synergistic effects when 
anti-proliferative activity was evaluated in LNCaP and C4-2 cell lines (Murga et al., 
2015).   
 
In preparing drug cocktails for combination therapy, it is highly desirable to achieve 
as low as possible drug doses within the cocktails. An ideal therapeutic cocktail 
should have the following attributes: (1) constituent drugs should not antagonise 
each other; (2) adequate synergy should exist between constituent drugs; (3) the 
safety profiles constituent drugs should not overlap, and (4) the therapeutic 
effectiveness of any constituent drug should not worsen adverse event signatures of 
the others. In this study, the modes of interaction of the dual inhibitor of PI3K and 
mTOR (NVP-BEZ235), EGRF inhibitor (AG-1478), and AR inhibitor (MDV3100) in in 
vitro cultures of four human prostate cell lines (DU145, LNCaP, BPH-1 and 1542N) 
were evaluated, as described elsewhere (Chou, 2006; Hamunyela et al., 2017). For 
this, the following cocktails were used: Cocktail 1 (AG-1478 and NVP-BEZ235), 
Cocktail 2 (NVP-BEZ235 and MDV3100), and Cocktail 3 (MDV3100 and AG-1478). 
The combination indices (CI) for each cocktail in the DU145, BPH-1 and 1542N cell 
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lines ranged between 0.0082 and 0.1591 (Table 3.6), indicating strong to very strong 
synergism for each inhibitor combination.  
 
Dual inhibition of the mitogen-activated protein kinase/extracellular-signal-
regulated kinase (MEK) and PI3K/mTOR pathways in DU145, LNCaP and PC-3 cell 
lines with AZD6244 and GSK2126458, respectively, also showed synergistic effects 
(Park et al., 2015). Synergistic effects have also been demonstrated for combination 
therapy castration-resistant prostate cancer with docetaxel and thymoquinone 
(Dirican et al., 2014). The very strong synergism observed for Cocktail 1 in DU145, 
BPH-1 and 1542N cells, Cocktail 2 in DU145 and LNCaP cells, and Cocktail 3 in 
DU145 and BPH-1 cells is consistent with that observed in human breast cell lines 
(Hamuneyela et al., 2017). Clinically, synergisms have also been demonstrated 
between AZD6363, bicalutamide, ADC, Enzalutamide and abiraterone in prostate 
cancer (Thomas et al., 2013; Murga et al., 2015).  
 
The scope of the current study cannot demonstrate that synergy observed may not 
be accompanied by an aggravation of adverse effects of the cocktails, as the 
interaction profiles were derived at high inhibitor concentrations. Besides, the data 
also show high synergy in the apparently normal cell line. However, the CI-values for 
Cocktails 1 and 3 in the androgen-dependent LNCaP cell line were greater than 1.0 
(Table 3.6), indicating antagonism between the constituent inhibitors. Inhibitor 
combinations with features akin to those of these cocktails may not be beneficial in 
the management of androgen-dependent cancers. Similar antagonism has been 
demonstrated in LNCaP and PC-3 cell lines when the AR and glucocorticoids 
receptor (GR) were dually inhibited (Wu et al., 2017).  
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4.4. Radiomodulation by Inhibitors 
 
4.4.1. Radiomodulation by AG-1478 and NVP-BEZ235 
 
Radiosensitisation of prostate cancer cells, specifically LNCaP, DU145, and BPH-1 
to radiation may be achieved by targeting pathways that are implicated in 
radioresistance, such as the PI3K/mTOR, EGFR and AR pathways (An et al., 2007; 
Skvortsova et al., 2008; Jain et al., 2012). This approach could lead to the 
enhancement of the efficacy of radiotherapy in CRPC. Many pre-clinical studies and 
clinical trials have tested this hypothesis, and clinically beneficial outcomes in 
numerous cancers have been documented (Li et al., 2010; Fokas et al., 2012; 
Bonner et ., 2006; Maira et al., 2008; Cho et al., 2010; Carver et al., 2011; Haffty et 
al., 2006; Kassam et al., 2009; Foulkes et al., 2010). We and others have reported 
the benefit of targeting these pathways in an effort to develop novel treatment 
approaches for breast and prostate cancer (Maleka et al., 2015; 2019; Hamunyela et 
al., 2015; 2016; 2017; Hamid et al., 2016). 
 
Research in breast, head and neck, and lung cancer, involving clinical trials which 
explore targeted and combination therapies, has yielded a wealth of knowledge. 
Examples of these research efforts are the following: (1) the targeting of EGFR 
overexpression in these cancers with receptor-blocking monoclonal antibodies (such 
as, cetuximab), or small molecule EGFR inhibitors (such as, gifitinib) (Liang et al., 
2003; Liu et al., 2010); (2) the inhibition of the PI3K/mTOR pathway with LY294002, 
NVP-BEZ235 and NVP-BGT226 (Toulany et al., 2006; Fokas et al., 2012); and (3) 
the inhibition of the androgen receptor pathway in triple negative breast cancer with  
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MDV3100 (Speers et al., 2017). These studies have demonstrated that such 
pathway inhibition sensitises cancer cells to the cytotoxic effect of ionising radiation. 
However, the extent of similar studies in prostate cancer, especially CRPC, is 
minimal or non-existent. 
 
Radiotherapy has remained a very important treatment modality in PCa 
management, but tumour resistance continues to be a major clinical challenge. In 
this study, the importance of conventional X-ray therapy has been demonstrated in 
three PCa cell lines and an apparently normal prostate cell line. The ranking of the 
cell line in order of increasing radiosensitivity is: DU145  BPH-1  1542N  
LNCaP, with only the androgen-dependent cell line being relatively more 
radiosensitive than the normal cell line. This would imply minimal to no therapeutic 
benefit of conventional radiotherapy for a majority of prostate cancers. On average, 
pre-treatment of tumour cell lines with the EGFR inhibitor (AG-1478) resulted in 
minimal or no radiosensitisation. However, pre-treatment of the with the PI3K/mTOR 
inhibitor (NVP-BEZ235), showed desirable results, especially at low therapeutic 
doses (e.g. 2 Gy), where radioprotection was seen in 1542N cells, while the tumour 
cells were radiosensitised by 38 - 69%. A similar radioprotection was previously 
demonstrated in this cell line and normal gut tissue (Potiron et al., 2013; Maleka et 
al., 2015). The present data suggest that combining X-rays with AG-1478 or NVP-
BEZ235 at high radiation doses may not be appropriate, as the normal cell line 
shows high levels of radiosensitisation compared to the rest of the cell line. For the 
tumour cell lines, the results from a combination of radiation and a cocktail of AG-
1478 or NVP-BEZ235 do not seem to differ greatly from those obtained from single 
inhibitor treatment prior to irradiation. This suggests that dual targeting of the EGFR 
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and PI3K/mTOR pathways may not have a therapeutic advantage over single 
pathway targeting.  
 
4.4.2. Radiomodulation by MDV3100 and NVP-BEZ235 
 
To explore the role of the androgen receptor (AR), which has been thought to be the 
core driving force for prostate cancer progression, the radiomodulatory effect of the 
AR inhibitor (MDV3100) was also evaluated in conjunction with PI3K/mTOR inhibitor 
(NVP-BEZ235).  
 
In the androgen-dependent cell line LNCaP, MDV3100 showed the greatest 
radiosensatation of almost 3-fold at low radiation doses and ~8-fold at high doses 
(Table 3.11). This may be attributed to the high levels of AR expression in these cells 
(Guo et al., 2000). These results are similar to those of the apparently normal cell 
line (1542N), which was radiosensitised up to 2- and 7-fold at low and high radiation 
doses, respectively. By definition, the 1542N cell line is androgen-independent. 
However, the current findings demonstrate that as the concentration of 5α-DHT 
increases in 1542N cell cultures, so does the cells shift from an androgen-
independent state to being androgen-dependent (Figure 3.2). In the traditionally 
androgen-independent cell lines (DU145 and BPH-1), the radiosensitisation by 
MDV3100 pre-treatment was minimal. This can be expected as these cell lines have 
been shown to express low levels of the androgen receptor (Guo et al., 2000). 
However, a switch from androgen-independent to androgen-dependent was 
apparent in the DU145 cell line (Figure 3.1), making the role of the AR pathway in 
radiation resistance unclear.   
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For cancers that behave like LNCaP, a cocktail of MDV3100 and NVP-BEZ235 could 
be an effective adjuvant to radiotherapy, as these cells were radiosentised by 
cocktail pre-treatment up to 4- and 21-fold at low and high doses, respectively (Table 
3.11). A potential benefit is also apparent in treating tumours that may be MDV3100-
resistant, as seen in the DU145 cell line, with MDV3100/NVP-BEZ235 cocktail prior 
to high doses of radiation. MDV3100-resistant prostate cancers constitute a 
significant clinical challenge (Kuruma et al., 2013). 
 
From the data presented here, it can be concluded that combined targeting of the 
PI3K/mTOR and AR pathways could potentially be an effective therapeutic strategy 
for androgen-dependent (whether intrinsic or switched on at high androgen levels) 
cancers. 
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CHAPTER 5: CONCLUSION 
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5. Conclusion 
 
In conclusion, these data demonstrate that increasing the levels of 5α-DHT might 
redefine the androgen sensitivity of human prostate cell lines, as 5α-DHT was seen 
to both inhibit and promote cell proliferation in the DU145 and 1542N cell lines. The 
reason for this disparity is currently not known. However, this observation might be 
useful in designing therapeutic interventions for both androgen-dependent and 
independent cancers. As it has been documented that ADT is adversely affected by 
tumour independence on androgen, switching cells from androgen-independent to 
androgen-dependent might be of therapeutic benefit when administrating ADT. A 
cocktail of PI3K/mTOR and AR inhibitor, as an adjuvant radiotherapy, may also be 
beneficial in the management of intrinsically androgen-dependent cancers.  
 
In the cell lines used in this study, the potential benefit of EGFR targeting is limited. It 
is also important to note that use of a cocktail of AG-1478 and NVP-BEZ235, or 
single inhibitors at high radiation doses may result in high levels of radiosensitisation 
of normal tissue. The cocktails, consisting of constituents at EC50, resulted in strong 
to very strong synergism when inhibitor interaction was tested in the cell lines, with 
the exception of the LNCaP cell line which demonstrated antagonistic effects. Use of 
an immortalised normal prostate cell line instead of normal cells derived from 
radiation dose limiting organs, such as the bladder and rectum, can significantly 
influence potential therapeutic benefit. Nonetheless, it is worth noting that unmodified 
normal cell lines are limited in their capacity to successfully complete intended 
clonogenic assays, as described in this study. These findings might assist in the 
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design of more effective treatment approaches for cancers that typically display 
resistance to radiotherapy and chemotherapy.  
 
6. Limitations of the Study 
 Normal and benign prostate cells do not divide indefinitely. For the assays 
described in dissertation, the apparently normal cell line (1542N) and the 
benign prostatic hyperplasia cell line (BPH-1) had to be transformed in order 
to be able to proliferate indefinitely. Therefore, data obtained with these cell 
lines might not give a true representation of the clinical response of normal 
tissue and benign tumours.  
 
 The use of a cocktail of AG-1478 and NVP-BEZ235, or single inhibitors, at 
large fractions of radiation absorbed doses (e.g. 6 Gy), which are clinically 
relevant in the treatment of PCa, might result in undesirably high levels of 
radiosensitisation of normal tissue. 
 
 The interaction profiles of the respective inhibitors, most of which were 
synergistic, were derived at high inhibitor concentrations (EC50). Given that 
this synergy was also seen in the apparently normal cells, determination of 
the mode of inhibitor interaction at lower concentrations might inform the 
design of a more appropriate treatment approach.  
 
7. Possible Future Avenues for Research 
 Androgen-independent prostate cancer is an untreatable form of prostate 
cancer in which the normal dependence on androgens for growth and survival 
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has been bypassed. It would be interesting to further investigate the possibility 
of switching cancer cells from androgen-independent to androgen-dependent 
and evaluating their subsequent response to various therapies.  
 
 The very strong synergism demonstrated with the respective cocktails at EC50 
which shows high synergism also in the apparently normal, which is not 
desirable. Validating the synergism throughout the PCa cell lines with 
relatively low EC50 would be highly desirable, as to limit adverse effects to the 
apparently normal cell line. 
 
 Furthermore investigate the role of androgens in chemoresistance and radio 
resistance. And determine major factors affecting radiosensitivity, such as 
DNA repair capacity, and determine the specific genes that are responsible in 
enhancing and promoting radioresistance. As it has been reported by 
Polkinghorn and colleagues (Polkinghorn et al. 2013) that there is a close 
interplay between androgen receptor signalling and cellular DNA damage 
response machinery. 
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International Journal of Radiation Research, January 2019 Volume 17, No 1 
PI3K and mTOR inhibitor, NVP-BEZ235, is more toxic 
than X-rays in prostate cancer cells 
INTRODUCTION 
 In addition to androgen therapy,                             
radiotherapy is a first line option for the                   
treatment of prostate cancer. Radiotherapy is a 
highly effective treatment option for localized 
prostate cancer with manageable                               
treatment-related side effects (1,2). A major                
challenge in radiotherapy is normal tissue                
toxicity and patients failing to achieve long-term 
tumor control. On the other hand, androgen 
therapy does not benefit patients with androgen
-independent cancers as these tumors do not 
respond to treatment (3). The prognosis for               
localized and regional prostate disease is good. 
However, with almost one million new cases of 
prostate cancer (PCa) and over a quarter of a 
million prostate cancer-related deaths recorded 
per year worldwide, PCa remains the second 
most common cancer in men, with increasing 
incidences and mortality rates globally, and also 
in sub-Saharan Africa (4,5).  With the                            
abovementioned problems, new treatment  
strategies are needed to address these                         
therapeutic dilemmas. 
Targeted therapies have emerged as                    
alternative treatment modalities to overcome 
the issue pertaining to treatment resistance and 
normal tissue toxicity (6,7,8,9). The use of different 
omics techniques has led to progress in the                
molecular classification of both early and late 
stage prostate cancer which may manifest itself 
S. Maleka, A.M. Serafin, J.M. Akudugu* 
 
Division of Radiobiology, Department of Medical Imaging and Clinical Oncology, Faculty of Medicine and Health 
Sciences, Stellenbosch University, Tygerberg 7505, South Africa 
ABSTRACT 
Background: Radiotherapy and adjuvant androgen deprivation therapy have 
historically been the first treatment choices for prostate cancer but treatment 
resistance often limits the capacity to effectively manage the disease. Therefore, 
alternative therapeutic approaches are needed. Here, the efficacies of radiotherapy 
and targeting the pro-survival cell signaling components epidermal growth factor 
receptor (EGFR), phosphoinositide 3-kinase (PI3K), and mammalian target of 
rapamycin (mTOR), with their respective inhibitors are compared. Materials and 
Methods: The cytotoxic effects of inhibitors of PI3K and mTOR (NVP-BEZ235) and 
EGFR (AG-1478), and X-rays, were evaluated in prostate cell lines (LNCaP: cancer; 
DU145: cancer; BPH-1: benign prostatic hyperplasia; 1542N: apparently “normal”) 
using a colony forming assay. The cells were exposed to a range of X-ray doses or 
varying concentrations of the inhibitors, to obtain cell survival curves from which 
relative sensitivities (RS) of the tumor cell lines were derived as the ratio of their 
sensitivities to that of the “normal” cell line. Results: The LNCaP cells trended to 
be more sensitive to X-rays and AG-1478 exposure than 1542N cells, with RS-
values of 1.65±0.48 (P=0.1644) and 1.37±0.22 (P=0.0822), respectively. NVP-
BEZ235 emerged as very cytotoxic in all tumor cell lines, yielding RS-values of 
3.69±0.83 (DU145; P=0.0025), 8.80±1.73 (LNCaP; P<0.0001), and 8.76±1.70 
(BPH-1; P=0.0011). Conclusion: These findings demonstrated that targeted 
therapy, specifically that using NVP-BEZ235, might result in a more effective 
treatment modality for prostate cancer than conventional radiotherapy.  
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in targeted, personalized therapies. NVP-
BEZ235, a dual inhibitor of PI3K and mTOR, is 
cytotoxic and yet has the potential to protect 
normal tissue (10-12) and sensitize cancer cells to 
radiotherapy (10,11,13,14,15,16,17).   
PI3K pathway-mediated cross-talk between 
the androgen receptor (AR), which plays a               
pivotal role in prostate malignancy, and EGFR, 
has been demonstrated, and underpinned by 
preclinical models (18-20). This cross-talk may 
present itself as an important mechanism during 
PCa progression, giving cells a survival                      
advantage, and might serve as a potential target 
for cancer therapy (21).   
In search of alternatives to radiotherapy, this 
study compares the efficacies of radiotherapy 
and targeting PI3K, mTOR, and EGFR with                  
specific inhibitors NVP-BEZ235 and AG-1478 
using four human prostate cell lines (DU145, 
LNCaP, BPH-1 and 1542N). The potential               
therapeutic benefit of each agent (radiation or 
inhibitor) is discussed.  
 
 
MATERIALS AND METHODS 
 
Cell lines and culture maintenance  
The apparently “normal” 1542N cell line 
(passage number: 18-25) was derived from the 
normal prostate epithelial tissue of a patient 
with primary adenocarcinoma of the prostate, 
and immortalised with the E6 and E7 genes of 
the human papilloma virus 16 (22). The cells were 
a gift from Prof JRW Masters (Prostate Cancer 
Research Centre, University College London, 
UK). The epithelial cell line, BPH-1 (benign                 
prostatic hyperplasia-1) (passage number: 2-7), 
was established from human prostate tissue  
obtained by transurethral resection. Primary cell 
cultures were immortalised with simian virus 40 
(SV40) large T-antigen (23). The cells were            
obtained from Professor SW Hayward 
(Department of Urology, University of California, 
USA). Although the link between BPH and PCa 
remains largely controversial, there is ample 
evidence to suggest that the former is a                 
precursor of the latter (24,25,26,27). Therefore, the 
BPH-1 cell line is considered as “malignant” in 
38 
the current study. The LNCaP cell line (passage 
number: 4-9) was established from a                  
supraclavicular lymph node metastasis of             
human prostatic adenocarcinoma (28), and was 
obtained from Professor Helmut Klocker 
(Department of Urology, University of             
Innsbruck, Austria). These cell lines were grown 
in Roswell Park Memorial Institute medium, 
RPMI-1640 (Sigma-Aldrich, USA; cat #: R8758) 
supplemented with 10% (5% for LNCaP)              
heat-inactivated foetal bovine serum (FBS) 
(HyClone, UK; cat #: SV30160.30IH), penicillin 
(100 U/ml) and streptomycin (100 mg/ml) 
(Lonza, Belgium; cat #: DE17-602E). The              
malignant DU145 (passage number: 7-18) cells 
were derived from a metastatic lesion of the  
central nervous system (29), and were a gift from 
Prof P Bouic (Synexa Life Sciences, Montague 
Gardens, South Africa). Cells were routinely 
grown in Minimum Essential Medium (MEM) 
(Sigma-Aldrich, Germany). Growth media were 
supplemented with 10% heat-inactivated foetal 
bovine serum (FBS) (HyClone, UK; cat #: 
SV30160.30IH), penicillin (100 U/ml) and  
streptomycin (100 µg/ml) (Lonza, Belgium; cat 
#: DE17-602E). All cell cultures were grown as 
monolayers in 75-cm2 flasks (Greiner Bio-One, 
Germany; cat #: 658170) and were maintained 
by incubation at 37ºC in a humidified (relative 
humidity: 84%) atmosphere (95% air and 5% 
CO2). Cell cultures were used for experiments 
upon reaching 70-90% confluence. 
 
Inhibitors 
NVP-BEZ235 (C30H23N5O; Mw = 469.55; Santa 
Cruz Biotechnology, TX, USA, cat # 364429) is a 
dual inhibitor of phosphoinositide-3-kinase 
(PI3K) and mammalian target of rapamycin 
(mTOR), with an inhibitory concentration at 
50% (IC50) of ~5 nM for PI3K and 6 nM for 
mTOR, and shown to have IC50-values ranging 
from ~12 to 17 nM for inhibiting in vitro               
proliferation and survival of prostate cancer cell 
lines, PC3M, PC3, and DU145 (11,30). AG-1478 
(C16H14ClN3O2.HCl; Mw = 352.22; Tocris                 
Bioscience, UK, cat # 1276) is a specific inhibitor 
of EGFR with an IC50 of 3 nM, and has been 
shown to have an IC50 of 1 μM for inhibiting in 
Int. J. Radiat. Res., Vol. 17  No. 1, January 2019 
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vitro proliferation of a non-small cell lung cancer 
cell line, NCI-H2170 (31). Stock solutions of              
NVP-BEZ235 (106 mM) and AG-1478 (10 mM) 
were prepared in dimethyl sulfoxide (DMSO) 
and stored at -20°C until used. 
   
Cell culture irradiation and inhibitor                  
treatment  
Monolayer cell cultures of DU145, 1542N, 
LNCaP, and BPH-1 in exponential growth were 
trypsinized to give single-cell suspensions and 
were plated for X-ray exposure (300-100000 
cells per flask, adjusted for irradiation dose), and 
for inhibitor treatment (1000-4000 cells per 
flask, adjusted for inhibitor concentration)  into 
25-cm2 culture flasks (Nest Biotechnology,               
China; cat #: 707001). The cell cultures in 10 ml 
of growth medium were incubated for 4-5 h (4-7 
h for LNCaP) to allow the cells to attach. The 
LNCaP cell line has altered adhesion properties 
(low anchoring potential) which explains why 
the cells are left to settle for a longer period of 
time (28). The attached cells were then irradiated 
with X-rays or treated with inhibitors of PI3K 
and mTOR (NVP-BEZ235) and EGFR (AG-1478), 
respectively. For X-ray exposure, cell cultures 
were irradiated at room temperature (22ºC) to 0
-10 Gy using a Faxitron MultiRad 160                           
X-irradiator (Faxitron Bioptics, Tucson, AZ) at a 
dose rate of 1 Gy/min. Cell cultures were treated 
with inhibitors, without media replacement. 
Cells were exposed to NVP-BEZ235 (0.001-1,000 
nM) and AG-1478 (1-100,000 nM) after                    
appropriate dilution of stock solutions in cell 
culture medium. 
  
Radiosensitivity and inhibitor toxicity                 
measurement 
The colony assay was used to measure            
intrinsic cellular radiation response, and                  
cytotoxicity of inhibitors. Briefly, irradiated and 
inhibitor-treated cells were incubated for 10 
days (BPH-1 and DU145) and 14 days (LNCaP 
and 1542N) to form colonies. To test for possible 
inhibitor solvent toxicity, two sets of control 
(untreated) cultures were prepared for each  
experiment. One set was exposed to DMSO at a 
final concentration corresponding to that of the 
highest inhibitor concentration, and the              
resulting plating efficiencies of the control             
culture sets compared. The experiments were 
stopped by decanting the growth medium,          
washing with phosphate buffered saline, and 
fixing with glacial acetic acid:methanol:water 
(1:1:8, v/v/v). The colonies were stained with 
0.01% amido black in fixative, washed in tap  
water, air-dried, and counted using a                     
stereoscopic microscope (Nikon, Japan; Model #: 
SMZ-1B). Three independent experiments were 
performed for each radiation dose and inhibitor 
concentration, and the mean surviving fractions 
were calculated. Surviving fractions (SF) were 
calculated according to the formula, SF=ncol(t)/
{[ncol(u)/ncell(u)]×ncell(t)}, where ncell(t) and ncell
(u) represent the number of cells plated in treated 
(irradiated or inhibitor treated) and untreated 
(control) cultures, respectively. ncol(t) and ncol(u) 
are the corresponding number of colonies  
counted. No inhibitor solvent related toxicity 
was observed in control (untreated) cultures 
containing the highest concentration of DMSO 
(0.000066% for NVP-BEZ235 at 1:10000                
dilution of stock; and 0.1% for AG-1478 taken 
directly from stock).   
Cell survival data for X-ray exposure were 
fitted to the linear-quadratic (LQ) model to            
generate survival curves (equation (1)), and  
cellular radiosensitivity, expressed in terms of 
the absorbed radiation dose at which 50% cell 
killing occurred (D50), was determined.  
 
S = exp [ -αD -βD2 ]                 (1) 
 
where S is the surviving fraction, α and β are 
the linear and quadratic coefficients,                           
respectively, and D is the absorbed dose in Gy. 
To determine the equivalent concentration of 
each inhibitor for 50% cell killing (EC50), the   
surviving fractions were plotted as a function of 
log (inhibitor concentration) and were fitted to a 
4-parameter logistic equation describing a              
sigmoidal curve (equation (2)) (16,33,34). 
 
        (2) 
 
where B and T are the minimum and                  
maximum of the sigmoidal curve, respectively, D 
is the log(inhibitor concentration), and HS is the 
Maleka et al. / Therapeutic advantage of PI3K and mTOR inhibition 
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steepest slope of the curve.  
To determine whether a treatment agent                 
(X-rays or inhibitor) had a potential therapeutic 
benefit, a relative sensitivity (RS) was derived 
by comparing the D50 and EC50 of the “normal”              
prostate cell line, (1542N), with those of the   
tumor cell lines (DU145, LNCaP, BPH-1) as              
follows: 
 
    (3) 
 
The criteria for no potential benefit with  
possible undesirable effects, no potential                  
benefit, and potential therapeutic benefit of each 
agent are RS<1.0, RS=1.0 and RS>1.0,                            
respectively. 
 
Data analysis 
Statistical analyses were performed using the 
GraphPad Prism (GraphPad Software, San Diego, 
CA, USA) computer program. The relationship 
between cell survival and X-ray dose was                 
described using a linear-quadratic equation. A          
4-parameter logistic equation describing a               
sigmoidal curve was used to describe the                   
relationship between inhibitor cytotoxicity (cell 
survival) data and inhibitor concentration. 
Standard equations were used to fit nonlinear 
relationships. All data presented in figures and 
used in curve fitting were calculated as the 
means (± SEM) from three independent                     
experiments. For each experiment and data 
point, 3 replicates were assessed. To compare 
two data sets, the unpaired t-test was used.               
P-values and coefficients of determination, R2, 
were calculated from two-sided tests. A P-value 
of <0.05 indicated a statistically significant              
difference between the data sets.  
 
 
RESULTS 
 
Intrinsic cellular radiosensitivity  
Cell survival data for the human prostate  
carcinoma and “normal” cell lines were fitted to 
the linear-quadratic model, and the                             
corresponding dose-response curves are              
presented in figure 1. Intrinsic cellular              
radiosensitivity was expressed in terms of the 
radiation dose at which a cell survival of 50% 
(50% cell killing) was obtained (D50), and was 
presented as the mean (±SEM). The                     
androgen-dependent cell line, LNCaP, emerged 
as more radiosensitive than its                             
androgen-independent counterparts (1542N, 
BPH-1, DU145). The rank order of                               
radioresistance in the cell lines was found to be 
LNCaP<1542N<BPH-1<DU145, with D50-values 
of 0.93 ± 0.19, 1.53 ± 0.32, 1.65 ± 0.36, and 2.25 ± 
0.54 Gy, respectively. No statistically significant 
differences emerged between the                                
radiosensitivity of the “normal” cell line when 
compared with those of the tumor cell lines as 
presented in table 1 (0.1644 ≤ P ≤ 0.7797). This 
translated to relative sensitivities (RS) that do 
not differ significantly from unity. The                      
corresponding RS-values for the DU145, LNCaP, 
and BPH-1 cell lines were 0.68 ± 0.21, 1.65 ± 
0.48, and 0.93 ± 0.28, respectively (table 1).    
 
Cytotoxicity of EGFR inhibitor (AG-1478) 
Figure 2 shows that the EGFR inhibitor                   
AG-1478 exhibits a concentration-dependent 
toxicity in all cell lines, and sensitivity to                  
inhibitor treatment was expressed in terms of 
equivalent concentration for 50% cell killing 
(EC50) as the mean (±SEM). Treatment with              
AG-1478 yielded the same sensitivity ranking, as 
observed for X-ray exposure (figure 2), with the 
LNCaP showing more sensitivity than the other 
cell lines. The EC50 of the “normal” cell line 
(1542N) emerged as 400 ± 38 nM and was            
significantly lower than those of the DU145 
(6613 ± 1510 nM, P = 0.0147, R2 = 0.8088) and 
BPH-1 (677 ± 41 nM, P = 0.0079, R2 = 0.8588) 
cell lines. The EC50 of the relatively more               
sensitive LNCaP cell line did not differ                        
significantly from that of the 1542N cell line 
(302 ± 19 nM, P = 0.0822, R2 = 0.5712). This               
resulted in very low relative sensitivities of 0.06 
± 0.02 and 0.59 ± 0.07 for the DU145 and BPH-1 
cell lines (table 2), as determined from equation 
(3), respectively. The relative sensitivity of the 
LNCaP cell line was 1.33 ± 0.15.  
Maleka et al. / Therapeutic advantage of PI3K and mTOR inhibition 
Int. J. Radiat. Res., Vol. 17  No. 1, January 2019 40 
D
ow
nl
oa
de
d 
fro
m
 ijr
r.c
om
 at
 19
:24
 +0
43
0 o
n T
hu
rsd
ay
 M
ay
 16
th 
20
19
Stellenbosch University https://scholar.sun.ac.za
Cytotoxicity of PI3K and mTOR inhibitor                
(NVP-BEZ235)  
Inhibition of PI3K and mTOR inhibitor with 
NVP-BEZ235 also resulted in a                                        
concentration-dependent cell killing, as shown 
in figure 3. The rank order of cytotoxicity                    
following NVP-BEZ235 treatment is LNCaP≈BPH
-1<DU145<1542N, with EC50-values of 6.10 ± 
0.40, 6.11 ± 0.64, 16.25 ± 4.72, and 53.82 ± 2.95 
nM, respectively. All tumor cell lines were                  
significantly more sensitive to NVP-BEZ235 
treatment than the “normal” cell line as shown 
in table 2 (P ≤ 0.0025). The tumor cell lines, 
DU145, LNCaP, and BPH-1, were found to be              
3- to 8-fold more sensitive than the “normal” cell 
line (1542N) with relative sensitivities of 3.31 ± 
0.98, 8.82 ± 0.75, and 8.81 ± 1.04, respectively 
(equation (3), table 2).  
Maleka et al. / Therapeutic advantage of PI3K and mTOR inhibition 
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Table 1. Summary of cytotoxicity data for 4 human prostate cell lines (“normal”: 1542N; cancer: DU145, LNCaP; benign prostate 
hyperplasia: BPH-1) and relative radiosensitivity determined by clonogenic cell survival after exposure to X-rays. D50 denotes the 
absorbed radiation dose required to yield a 50% cell killing (figure 1). The 95% confidence intervals of the D50-values are in                  
parentheses. P-value indicates the level of significance in the difference  between the D50 of the “normal” cell line (1542N) relative 
to those of the  tumor cell lines (DU145, LNCaP, BPH-1). Relative sensitivity (RS) is the ratio of the D50 of the “normal” cell line to 
those of the tumor cell lines. α and β are the linear and quadratic coefficients of the respective cell survival curves obtained from 
the LQ-model (equation (1)). 
Cell line α (Gy-1) β (Gy-2) D50 (Gy) P-value   RS 
1542N 0.49 ± 0.11 0.00 ± 0.00 
1.53 ± 0.32 
(1.17-2.17) 
− − 
DU145 0.28 ± 0.06 0.01 ± 0.01 
2.25 ± 0.54 
(0.59-3.90) 
0.2261 0.68 ± 0.21 
LNCaP 0.78 ± 0.24 0.02 ± 0.02 
0.93 ± 0.19 
(0.37-1.50) 
0.1644 1.65 ± 0.48 
BPH-1 0.39 ± 0.05 0.04 ± 0.01 
1.65 ± 0.36 
(0.57-2.73) 
0.7797 0.93 ± 0.28 
Figure 1. Clonogenic cell survival curves for 4 human prostate cell lines [DU145 (●), LNCaP (□), BPH-1 (▲), 1542N (■)] after X-ray                 
irradiation. Survival curves were obtained by fitting experimental data to the linear-quadratic model. Symbols represent the mean 
surviving fraction ± SEM from 3 independent experiments. Standard errors are not transformed into a logarithmic scale. The dose 
at which 50% of cells survive (D50) is the dose at which each survival curve intersects the horizontal dashed line. D
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Cell line Treatment EC50 (nM) P-value   RS 
1542N 
AG-1478 400 ± 38 (237-563) − − 
NVP-BEZ235 53.82 ± 2.95 (41.13-66.50) − − 
 DU145 
AG-1478 6613 ± 1510(116-13110) 0.0147 0.06 ± 0.02 
NVP-BEZ235 16.25 ± 4.72 (11.83-36.57) 0.0025 3.31 ± 0.98 
LNCaP 
AG-1478 302 ± 19 (220-384) 0.0822 1.33 ± 0.15 
NVP-BEZ235 6.10 ± 0.40 (4.39-7.81) <0.0001 8.82 ± 0.75 
BPH-1 
AG-1478 677 ± 41 (499-855) 0.0079 0.59 ± 0.07 
NVP-BEZ235 6.11 ± 0.64 (3.96-14.17) 0.0011 8.81 ± 1.04 
Table 2. Summary of cytotoxicity data for 4 human prostate cell lines (1542N, DU145, LNCaP, BPH-1) treated with EGFR inhibitor 
(AG-1478) and PI3K and mTOR inhibitor (NVP-BEZ235). EC50 denotes the equivalent concentration for 50% cell survival (figures 2 
and 3). The 95% confidence intervals of the EC50-values are in parentheses. P-value indicates the level of significance in the              
difference between the EC50 of the “normal” cell line (1542N) relative to those of the tumor cell lines (DU145, LNCaP, BPH-1).  Rela-
tive sensitivity (RS) is the ratio of the EC50 of the “normal” cell line to those of the tumor cell lines. 
Figure 2. Cytotoxicity curves for EGFR inhibitor (AG-1478) 
treatment of 4 human prostate cell lines (DU145, 1542N, 
LNCaP, BPH-1). Curves were obtained by plotting cell survival 
as a function of log (inhibitor concentration). Cell survival was 
determined by the colony assay, and data were fitted to a 
sigmoidal equation. Data points are means ± SEM of 3            
independent experiments. The concentration at which 50% of 
cells survive (EC50) is that at which each survival curve              
intersects the horizontal dashed line. 
Figure 3. Cytotoxicity curves for PI3K and mTOR inhibitor (NVP
-BEZ235) treatment of 4 human prostate cell lines (DU145, 
1542N, LNCaP, BPH-1). Curves were obtained by plotting cell 
survival as a function of log (inhibitor concentration). Cell           
survival was determined by the colony assay, and data were 
fitted to a sigmoidal equation. Data points are means ± SEM of 3 
independent experiments. The concentration at which 50% of 
cells survive (EC50) is that at which each survival curve              
intersects the horizontal dashed line. 
DISCUSSION 
Using the clonogenic survival assay, it is 
demonstrated for 4 human prostate cell lines 
that there is no significant therapeutic                   
advantage when D50-values of the tumor cell 
lines (LNCaP, BPH-1, DU145) were compared 
with that of the “normal” cell line (1542N) 
(figure 1, table 1). The ranking order, from most 
radiosensitive to least radiosensitive using X-ray 
irradiation, is LNCaP>1542N>BPH-1>DU145, 
and is in close agreement with radiosensitivity 
data reported previously for these cell lines             
following cobalt-60 γ-ray exposure (35). The            
absence of a therapeutic benefit may be            
explained by the fact that the D50-values are    
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derived at 50% cell survival which coincides 
with the shoulder region of the survival curves, 
and may not differ markedly. For instance, a 
comparison of doses at the level of 10% survival, 
yields relative sensitivities of 1.77, 1.18, and 
0.78, for the LNCaP, BPH-1, and DU145 cell lines, 
respectively, indicating a potential benefit for 
the former two. However, the rationale for 
choosing D50 and EC50 was to enable comparison 
of the relative sensitivities (RS) of the cell lines 
at the same level of survival, when as low as  
possible radiation dose or inhibitor                        
concentration is administered. It should also be 
acknowledged that molecular assays have been 
developed applying multigene expression                
profiles to predict tumor radiosensitivity by 
comparisons with clonogenic survival data from 
established cell lines (36,37), that likely have the 
most potential for clinical implementation. Such 
methods have been shown to be statistically   
predictive of tumor response in esophageal and 
rectal cancers, and of locoregional control in 
head and neck cancers (37).  As such, there is the 
need to explore avenues like the inhibition of 
EGFR, PI3K, and mTOR, described here. 
The cytotoxic effects of AG-1478 (EGFR              
inhibitor) and NVP-BEZ235 (PI3K and mTOR 
inhibitor) are concentration-dependent (figures 
2 and 3). For AG-1478, EC50 values ranged from 
302–6613 nM (figure 2, table 2), giving relative 
sensitivities of less than 1.0 for the                        
androgen-independent DU145 and BPH-1 cells. 
This clearly shows that the “normal” cells 
(1542N) are more sensitive to EGFR inhibition 
than their tumor counterparts and use of                  
AG-1478 for treatment of prostate cancer might 
lead to undesirable outcomes. However,                  
inhibiting EGFR in the androgen-dependent 
LNCaP cells showed a small therapeutic benefit, 
with a relative sensitivity of 1.33 (table 2). The 
significant level of resistance to EGFR inhibition 
seen in the DU145 and BPH-1 cell lines (relative 
sensitivities of 0.06 and 0.59, respectively)             
relative to the LNCaP cell line is likely due to the 
fact that EGFR expression in the former is over 5
-fold that in the latter (38,39,40). Higher EGFR         
expression levels would require significantly 
larger concentrations of inhibitor to achieve a 
given proportion of cell killing. On the other 
hand, EGFR expression in the                                      
androgen-dependent LNCaP cells is low and                    
comparable to that in the “normal” 1542N cells 
(41), consistent with the observed relative                      
sensitivity of 1.33 ± 0.15.  
For NVP-BEZ235 treatment, EC50 values 
ranged from 6.10–53.82 nM for all cell lines 
(figure 3, table 2), and are consistent with those 
recently reported for human breast cell lines (16). 
Here, the “normal” cell line (1542N) is clearly 
the most resistant to PI3K and mTOR inhibition, 
making the tumor cell lines 3 to 8 times more 
sensitive (table 2). This resistance can be              
attributed to NVP-BEZ235 being specifically 
more toxic to malignant cells, as reported               
elsewhere (42). The sensitivity ranking of the             
malignant cell lines (DU145 and LNCaP) may be 
related to the extent to which NVP-BEZ235              
inhibits the activity of key components of the 
PI3K/mTOR pathway, such as,  PDK1Ser241,               
AktThr308, AktSer473, GSK3bSer19, FoxolaSer256, 
S6KSer235/236, 4EBP1Thr27/66, and MDM2Ser166. On 
average, inhibition of activity of these                          
components by a dual PI3K/mTOR inhibitor 
(XL765) has been shown to be about 2-fold 
more effective in the LNCaP cell line than the 
DU145 cell line (43). The clonogenic cell survival 
data presented here are consistent with this, 
with the LNCaP cells being 2.7-fold more                   
sensitive than the DU145 cells (Table 2).                  
However, the similarity in NVP-BEZ235                     
cytotoxicity in LNCaP and BPH-1 (EC50 of 
6.10±0.40 and 6.11±0.64, respectively) cannot 
be corroborated by the finding that NVP-BEZ235 
is about 10-fold less effective in inhibiting cell 
proliferation than the latter cell line (43). This 
disparity is likely due to differences in                      
experimental design and endpoints. While the 
clonogenic cell survival assay described here 
takes about 2 weeks and reflects delayed effects 
of PI3K and mTOR inhibition, the cell growth 
assay of Gravina et al. lasts only 24 hours and 
could miss such effects (43).  
Use of an immortalized “normal” prostate cell 
line instead of normal cells derived from                   
radiation dose limiting organs, such as the               
bladder and rectum, can significantly influence 
potential therapeutic benefit. Nonetheless, it is 
worth noting that unmodified normal cell lines 
Maleka et al. / Therapeutic advantage of PI3K and mTOR inhibition 
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are limited in their capacity to successfully            
complete intended clonogenic assays, as              
described in this study.  
In conclusion, these data demonstrate that 
concomitant inhibition of PI3K and mTOR may 
have a higher therapeutic benefit in the                  
treatment of androgen-dependent and                           
-independent prostate cancers, compared to  
conventional radiotherapy or EGFR-targeted 
therapy. The findings might assist in the design 
of more effective treatment approaches for            
cancers that typically display resistance to             
radiotherapy and chemotherapy.  
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